Document:

exv10w28

 

Exhibit 10.28

COMMERCIAL SUPPLY AGREEMENT

     This Commercial Supply Agreement (this “Agreement”) is made as of the ___ day of September,
2007 (the “Effective Date”) by and between Omeros Corporation, a Washington corporation, having its
principal offices at 1420 Fifth Avenue, Suite 2600, Seattle, Washington 98101 (“Omeros”), and
Hospira Worldwide Inc., a Delaware corporation, having its principal offices at 275 North Field
Drive, Lake Forest, Illinois 60045 (“Hospira”). Omeros and Hospira previously entered into a
Master Development Agreement, dated May 8, 2007 (the “Development Agreement”), pertaining to the
development of Omeros’ pharmaceutical drug product OMS103HP-S. Omeros and Hospira now desire to
enter into an agreement for the commercial supply of OMS103HP-S by Hospira to Omeros. Therefore,
in consideration of the mutual covenants and obligations set forth below, Omeros and Hospira (the
“Parties” and each a “Party”) agree as follows:

     1. DEFINITIONS

     The following initially capitalized terms in this Agreement, whether used in the singular or
plural, shall have the respective meanings set forth below:

     1.1 “Act” means U.S. Federal Food, Drug and Cosmetic Act, 21 U.S.C. §301 et seq.

     1.2 “Affiliate” means any corporation or other entity or enterprise that controls, is
controlled by, or is under common control with, a Party. A corporation or other entity or
enterprise shall be regarded as in control of another corporation, entity or enterprise if it owns
or directly or indirectly controls 50% or more of the voting securities or other ownership interest
of the other corporation, entity or enterprise or if it possesses, directly or indirectly, the
power to direct or cause the direction of the management and policies of the corporation or other
entity or enterprise.

     1.3 “APIs” means the active pharmaceutical ingredients required for the Processing of Product
as set forth in the Specifications.

     1.4 “Applicable Laws” means all laws, ordinances, rules and regulations applicable to the
Product and the Services (including Processing of Product or any aspect thereof) and the
obligations of Hospira or Omeros, as the context requires under this Agreement, including, without
limitation, (a) all applicable federal, state and local laws and regulations, including without
limitation the Act, (b) all applicable FDA regulations promulgated under the Act, (c) all
applicable cGMPs, (d) all applicable guidances promulgated or adopted by FDA, including without
limitation all applicable International Conference on Harmonization (“ICH”) guidances, each as
amended from time to time and (e) all laws and regulations within the Territory, including without
limitation ICH guidances, that are applicable to the Processing of Product for commercial supply.

     1.5 “Batch” means the Product, made in accordance with the Specifications, resulting from a
single production run, or any other specific quantity of Product that is mutually agreed upon in
writing by the Parties from time to time.

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO
A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

 

     1.6 “Batch Records” means Batch-specific manufacturing, packaging and test records and
documentation relating to Processing, packaging and release of each Batch, exception documentation,
deviations/discrepancies and additional documentation generated and/or processed as part of the
production record of the related Batch.

     1.7 [†]

     1.8 “Certificate of Analysis” means, for each Batch produced, a document prepared by Hospira
setting forth the measured and observable characteristics of Product from the Batch, and confirming
that such Batch meets the Specifications. Each Certificate of Analysis shall include: (a) a
listing of tests performed by or on behalf of Hospira, test date(s), and test results, and a
certification of the accuracy of each of the foregoing; and (b) a reference to or inclusion of the
related Certificate of Compliance. The Parties shall from time to time agree upon a format or
formats for the Certificate of Analysis to be used under this Agreement.

     1.9 “Certificate of Compliance” means, for each Batch, a document prepared by Hospira: (a)
listing the manufacturing date, unique Batch number, and quantity of Product in such Batch, and (b)
certifying that such Batch was manufactured in accordance with Applicable Laws, including, without
limitation, cGMP. The Parties shall from time to time agree upon a format or formats for the
Certificate of Compliance to be used under this Agreement. The Certificate of Compliance may be
included within the Certificate of Analysis.

     1.10 “cGMP” means current Good Manufacturing Practices as defined in the FDA rules and
regulations, including, without limitation, the United States regulations set forth at 21 CFR Parts
210-211, as appropriate and as the same may be amended from time to time.

     1.11 “Confidential Information” means any data, research, development, manufacturing,
marketing, financial, personnel, sales, business, and other non-public, proprietary or technical
information provided by the disclosing Party to the Recipient, including without limitation all
Product Data (which shall be considered Omeros’ Confidential Information even if generated or
provided by Hospira), except any portion of such information that:

     (a) is or becomes generally available to the public or within the industry to which
such information relates, other than as a result of a breach of this Agreement; or

     (b) is known by Recipient at the time of receipt of the disclosing Party’s information,
as evidenced by Recipient’s contemporaneous written records; or

     (c) is provided to Recipient on a non-confidential basis by a third party who has the
legal right to make such disclosure; or

     (d) was or is independently developed by or for Recipient without access to or use of
the information of the disclosing Party, as evidenced by Recipient’s contemporaneous written
records.

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO
A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

2

 

     1.12 “Deliver” or “Delivery” with respect to Product means, and shall take place upon, the
transfer of possession of Product to Omeros [†] for Product delivered in the United States and [†]
for Product delivered outside of the United States.

     1.13 “Develop” or “Development” shall mean the generation, improvement, optimization, transfer
or validation of methods, assays, protocols or processes for Processing, analyzing or testing
Product.

     1.14 “Facility” means Hospira’s pharmaceutical manufacturing facility in McPherson, Kansas.

     1.15 “FDA” means the United States Food and Drug Administration and any successor agency.

     1.16 “Hospira New IP” shall mean all Intellectual Property conceived solely by Hospira during
the course of the performance of the Services pursuant to this Agreement, or conceived by Hospira
prior to this Agreement (other than pursuant to the Development Agreement) and reduced to practice
solely by Hospira during the course of the performance of the Services pursuant to this Agreement,
that is not specific to [†].

     1.17 “Intellectual Property” means all intellectual property (whether or not patented or
patentable), including, without limitation, inventions, patents, patent applications, trade
secrets, know-how, copyrights, trademarks, designs, concepts, technical information, manuals,
standard operating procedures, instructions or specifications.

     1.18 “Joint New IP” shall mean Intellectual Property conceived or reduced to practice jointly
by Hospira and Omeros excluding all Omeros New IP.

     1.19 “Latent Defect” means the failure of any Product delivered to Omeros to meet the current
Specifications at the time of manufacture as a result of the acts or omissions of Hospira or its
employees, subcontractors, agents or other representatives that was not, and could not reasonably
be expected to have been, found by exercise of ordinary care in inspection and testing by Omeros.
For purposes of clarity, the presence of a contaminant from Processing or Hospira’s failure to
comply with cGMPs shall be considered a Latent Defect.

     1.20 “Master Batch Record” shall mean the formal set of instructions for Processing of
Product.

     1.21 “Materials” means, collectively, all raw materials and other ingredients (excluding APIs)
and packaging and shipping materials required for Processing Product.

     1.22 “Minimum Percentage” shall initially mean [†] of Omeros’ Product Requirements and
subsequently any adjusted percentage of Omeros’ Product Requirements as may be mutual agreed in
writing by the Parties in accordance with Section 2.6.1, 3.9.1 or 3.10.6.

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO
A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

3

 

     1.23 “Omeros New IP” means any and all Intellectual Property conceived or reduced to practice
by either Party individually or jointly during the course of the performance of this Agreement that
are specific to [†].

     1.24 “Omeros’ Product Requirements” means Omeros’ total requirements for commercial sales of
Product in the Territory as well as clinical supplies of Product for the development of additional
therapeutic indications after Launch.

     1.25 “Omeros Property” means any chemical and/or biological materials or samples, other
tangible property, and written or electronic documents and records owned by or licensed to Omeros
as of the Effective Date, developed by Omeros in connection with this Agreement, or disclosed or
delivered by or on behalf of Omeros in connection with this Agreement, including, without
limitation, Omeros Confidential Information (including without limitation Product Data) and Omeros’
Intellectual Property (including without limitation Omeros New IP) in tangible or electronic form.

     1.26 “Price” means the [†] price of the Product, as set forth on Exhibit B attached
hereto and incorporated herein.

     1.27 “Process” or “Processing” shall mean the act or acts of manufacturing, handling, storing,
analyzing, testing, filling, finishing, packaging, inspecting, labeling, preparing for shipment
and/or stability testing of Product by Hospira pursuant to this Agreement.

     1.28 “Product” means a liquid formulation of Omeros’ pharmaceutical product, designated as
OMS103HP-S, which contains each of the following APIs: amitriptyline hydrochloride, oxymetazoline
hydrochloride and ketoprofen.

     1.29 “Product Data” means all information, documents, records, raw data, specimens, and other
work product that relates to or describes the Services, including the Processing of Product. The
term “Product Data” shall include, without limitation, documents and records pertaining to
Processing of Product, Batch Records, Certificates of Analysis, Certificates of Compliance,
analytical test methods, analytical test results, list of SOPs, Product Specific SOPs, list of
equipment used in the Processing of Product, signed title pages of approved qualification reports
for such equipment, general facility layout details and process trend and variability data, and all
other documents, reports and data prepared, developed or generated by Hospira in connection with
performance of the Services hereunder. The term “Product Data” shall expressly exclude, however,
General SOPs and other information that is Hospira’s confidential information that is not specific
to Omeros or Omeros’ Product and is related to Hospira’s manufacturing processes that are generally
applicable to the products of multiple customers.

     1.30 “Recipient” means a Party that receives Confidential Information.

     1.31 “Regulatory Authority” means any governmental regulatory agency or authority that is
responsible for regulating any aspect of the development, manufacture, market approval, sale,
distribution, packaging or use of the Product, including, without limitation, as applicable, based
on the Territory on the Effective Date or any expansion of the Territory by mutual written
agreement of the Parties, the FDA, the European Medicines Agency (EMEA), the Japanese

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO
A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

4

 

Ministry of Health, Labour and Welfare (MHLW), the Health Canada – Therapeutic Product
Programme (TPP) and any additional governmental agencies as agreed upon by the Parties based on
expansion of the Territory.

     1.32 “Services” means all services performed and activities conducted by Hospira (including,
without limitation, those related to process improvements and Processing of Product, as applicable)
pursuant to this Agreement and the Specifications.

     1.33 “SOPs” means Hospira’s standard operating procedures, and includes “General SOPs” that
are not specific to Processing of Product and “Product Specific SOPs” that are specific to the
Processing of Product.

     1.34 “Specifications” means the Product attributes listed on Exhibit A attached
hereto, which is incorporated into this Agreement, the Master Batch Record for Product, the master
packaging batch record for the Product, the labeling requirements for the Product, and all other
written specifications and/or instructions for measurable and observable qualities, characteristics
and attributes of Product and all other written requirements, standards, specifications, quality
assurance/quality control testing and release and other attributes pertaining to the Product and/or
Processing of Product, including APIs, other Materials and Third Party suppliers for Processing
Product, that are agreed to by the Parties (and as amended from time to time by Omeros in
consultation with Hospira, including, without limitation, such amendments as may be required to
obtain or maintain approval from the FDA or other Regulatory Authorities).

     1.35 “Technical Records” shall mean all books, records (including without limitation the
Master Batch Record and individual Batch Records for Product), test and laboratory data (including,
without limitation, Certificates of Analysis, SOPs and all other Product Data), reports and all
other information relating to the Services performed under this Agreement and the methods, Facility
and equipment used for Processing of Product or other Services.

     1.36 “Territory” shall mean [†].

     1.37 Additional Definitions.

	 	 	 	 
	Defined Term	 	Section in which Defined
	Agreement

	 	 Preamble
	[†]

	 	 10.4
	[†]

	 	 10.4
	Change Order

	 	 2.4
	Damages

	 	 9.2
	Development Agreement

	 	 Recitals
	DMF

	 	 5.2
	Effective Date

	 	 Preamble
	Executives

	 	 12.2
	Firm Commitment

	 	 3.9.2
	Firm Purchase Order

	 	 3.10.1
	General SOPs

	 	 1.33

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO
A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

5

 

	 	 	 	 
	Defined Term	 	Section in which Defined
	Hospira

	 	 Preamble
	Hospira Indemnitees

	 	 9.2
	ICH

	 	 1.4
	Indemnified Party

	 	 9.4
	Indemnifying Party

	 	 9.4
	Initial Term

	 	 10.1
	Launch

	 	 10.4
	Minimum Purchase Requirement

	 	 3.10.5
	NDA

	 	 3.9.2
	Omeros

	 	 Preamble
	Omeros Indemnitees

	 	 9.3
	Party and/or Parties

	 	 Preamble
	Product and Equivalents

	 	 7.1
	Product Specific SOPs

	 	 1.33
	Purchase Order

	 	 3.10.1
	Quality Agreement

	 	 3.2
	Representative

	 	 2.5
	Rolling [†] Estimate

	 	 3.9.1
	Rolling Forecast

	 	 3.9.2
	Stability Lot Price

	 	 3.7
	Submission

	 	 10.4
	Supply Period

	 	 10.4
	[†]

	 	 10.6.2
	Term

	 	 10.1

     2. COMMERCIAL SUPPLY

     2.1 Processing of Product. Omeros hereby engages Hospira, and Hospira hereby agrees, to
Process the Product for commercial sale by Omeros in accordance with the Specifications, and in
compliance with this Agreement and all Applicable Laws (including, without limitation, cGMPs). The
terms of this Agreement shall apply to the exclusion of and shall supersede the terms of any
purchase order, acknowledgement, confirmation, shipping document, or other document.

     2.2 Materials and Equipment. Unless otherwise agreed by the Parties in writing, Hospira shall
supply all Materials and standard processing and manufacturing equipment needed for Processing of
Product in accordance with this Agreement and the Specifications, at its sole cost and expense
(including, without limitation, shipping costs in connection with such Materials and equipment).

     2.2.1 Non-Standard Equipment. If dedicated or specialized equipment is required to Process
Product for Omeros, Hospira shall specify such equipment to Omeros in writing and, if Omeros agrees
in writing that such equipment is required, Omeros shall reimburse Hospira for

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO
A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

6

 

the cost of
purchasing such equipment, on a pass-through basis, as well as the reasonable cost of installation
and validation of such equipment, all subject to Omeros’ prior written approval or a
separate written agreement between the Parties with respect to such equipment purchase,
installation and validation. Title to such equipment shall be in Omeros’ name and, at Omeros’
request and reasonable expense, shall be returned to Omeros or discarded upon termination of this
Agreement. If Hospira wishes to use such equipment for Processing of a product other than Product
for Omeros, Hospira and Omeros shall meet and discuss the technical and practical ramifications of
such use and appropriate compensation to Omeros, but in no event is Omeros obligated to allow the
use of such equipment for the manufacture of such other product. These provisions shall not apply
to any non-dedicated or non-specialized equipment normally used or required for the manufacture of
pharmaceutical products, or to additional non-dedicated or non-specialized equipment required to
increase production capacity or efficiency at Hospira’s Facility.

     2.2.2 Labeling. Hospira shall label Product in accordance with Omeros’ instructions. Label
copy may be modified from time to time by written agreement of the Parties. Omeros shall reimburse
Hospira for Hospira’s actual costs of making any label copy changes and for the cost of any
labeling that Hospira is unable to use due to such label copy changes.

     2.3 Omeros’ Responsibilities and Authority. Unless otherwise agreed by the Parties in
writing, Omeros agrees that it will (a) provide APIs for processing of Product in accordance with
the provisions of Section 2.6,; (b) provide appropriate scientific data regarding the Product,
including, without limitation, appropriate and available safety and toxicity data, test methods and
formulation, fill and finish of the Product (as applicable); (c) provide Hospira with commercially
appropriate information necessary to Process the Product; (d) prepare and/or review and, if
acceptable to Omeros, approve all Specifications; and (e) as applicable, prepare all submissions to
Regulatory Authorities, portions of such that are relevant to Hospira which shall be subject to
review by Hospira as set forth in Section 5.8. Other than Processing of Product by Hospira in
accordance with this Agreement, Omeros shall retain sole authority and responsibility in all
matters related to commercialization of the Product.

     2.4 Specifications/Amendments/Changes.

     2.4.1 Specifications. The Master Batch Record and the Specifications shall be prepared and
maintained in Hospira’s standard format by Hospira, using Omeros’ master formula, other technical
information or standards that may be provided by Omeros, technical support provided by Omeros, and
labeling criteria (if applicable) provided by Omeros, and shall be approved in writing by Omeros.

     2.4.2 Changes to Specifications. Except as set forth in Section 2.4.3 below, if either Party
requests a change to the Specifications, Hospira shall provide Omeros with cost estimates for the
additional or repeat work related to such changes. If Omeros approves in writing such additional
or repeat work, Omeros shall be responsible for paying such costs if the changes are specific to
the Product, but not for regulatory mandated or plant upgrade changes that are required for
products in addition to the Product (which shall be approved pursuant to Section 2.4.3). If Omeros
approves such estimated costs, Hospira shall perform such work, and Omeros

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO
A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

7

 

shall pay Hospira’s
reasonable costs for such work within thirty (30) days of completion of such
work; provided that Hospira shall promptly notify Omeros in writing that such work has been
completed. Reimbursement for such additional work or repeat work shall be at the rate of [†].

     2.4.3 Regulatory Mandated Change to Specifications. If there is a change in Applicable Laws
that would necessitate a change in the Specifications, Processing or the means or methods of
performance under this Agreement by Hospira, the Parties will meet and confer in good faith to
determine whether and what changes (if any) should be made thereto and/or to the respective
responsibilities of the Parties therefor. Promptly after a request is made by Omeros for any such
change, or the Parties become aware of the change in Applicable Laws necessitating such change,
Hospira shall notify Omeros of any anticipated increase and/or decrease in the Price and any costs,
expenses or fees associated with such change. Omeros shall have the right to approve such change
and, if approved, the right to approve any corresponding revised Price and any reasonable costs,
expenses or fees associated with such change. No change in the Specifications, Product-specific
manufacturing processes, test methods, or other documentation or procedures relating to Processing
of Product or the Services shall be implemented by Hospira, whether initiated by Omeros or
requested or required by any Regulatory Authority, unless and until the Parties have executed a
written agreement documenting such change (“Change Order”), including the implementation date of
such change and any increase or decrease to the Price to reflect costs, expenses, fees or savings
associated with such change. If a Change Order is caused by a change clearly mandated or required
by any Regulatory Authority then approval of such Change Order shall not be withheld.

     2.4.4 Increases in Price. [†].

     2.5 Meetings; Communications. The Parties shall hold team meetings via teleconference,
videoconference or in person on a regular and periodic basis. Each Party shall appoint a
representative (each a “Representative”) who will have primary responsibility for day-to-day
interactions with the other Party’s Representative concerning the Processing of Product, the
Services and the activities of the Parties in connection with this Agreement. Unless otherwise
mutually agreed by the Parties in writing, all communications between Hospira and Omeros regarding
the Processing of Product, the Services and the activities of the Parties in connection with this
Agreement shall be addressed to or routed directly through (as appropriate) the respective
Representatives of each Party. Hospira shall provide periodic updates to Omeros regarding the
Processing of Product. These updates may be delivered by Hospira verbally, by telephone or
videoconference, or in writing, as mutually agreed upon by the Parties. Hospira shall notify
Omeros as soon as practicable (but in any event within twenty-four (24) hours) of any event or
condition, including without limitation technical deviations as addressed in Subsection 5.6 that is
likely to detrimentally impact or limit Hospira’s performance of the Services or Processing of
Product. Hospira shall notify Omeros as soon as practicable (but in any event within four (4)
business days) of any financial, legal or business condition that is likely to detrimentally impact
or limit Hospira’s performance of the Services or Processing of Product.

     2.6. Supply and Processing of Commercial Product; APIs.

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO
A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

8

 

     2.6.1 Commercial Product Supply; Minimum Percentage; Hospira Obligations Regarding Processing and
Services. Pursuant to the terms and conditions of this Agreement,
Omeros engages Hospira to supply, and Hospira agrees to manufacture, deliver and sell to Omeros,
Product intended for commercial sale. Hospira shall be obligated to supply, and Omeros shall be
obligated to purchase and take delivery of, the Minimum Percentage of Omeros’ Product Requirements
during the Term, which shall initially be [†] as set forth in Section 1.22. At any time during the
Term, Omeros and Hospira may mutually agree in writing to have Hospira supply and Omeros purchase a
percentage of Omeros’ Product Requirements that is greater than the initial Minimum Percentage as
provided for in Section 1.22. Hospira shall Process Product and perform all other services
(including Services) agreed upon by the Parties: (a) in accordance with the Specifications; (b) in
accordance with the Applicable Laws including, without limitation, cGMPs; and (c) in compliance
with this Agreement.

     2.6.2 Active Pharmaceutical Ingredient Supply. Hospira shall manufacture Product for Omeros
from APIs that Omeros shall supply at no cost to Hospira. Omeros shall supply APIs to Hospira in
quantities sufficient to satisfy Hospira’s gross manufacturing requirements of Product for Omeros.
Hospira’s use of APIs received from Omeros shall be limited to Processing of Product for Omeros as
contemplated by this Agreement. Omeros shall deliver or cause to be delivered APIs D.D.P.
(Incoterms 2000) Hospira’s designated Facility pursuant to no-cost purchase orders that Hospira
issues to Omeros. Within thirty (30) days of Hospira’s receipt of any APIs supplied by Omeros
hereunder, Hospira shall (a) perform identification, bacterial endotoxin and microbial limit
testing on the APIs and confirm the shipment quantity, and (b) notify Omeros of any inaccuracies
with respect to quantity or of any claim that any portion of the shipment fails the identification
test. In the event Hospira notifies Omeros of any deficiency in quantity of APIs received, Omeros
shall use reasonable commercial efforts to promptly ship to Hospira, at its own expense, the
quantity of APIs necessary to fulfill the original APIs shipment, unless Hospira and Omeros
mutually agree to a reduction in Product quantity to be Processed in accordance with
Section 3.10.2. Hospira recognizes that the APIs will be procured by Omeros from third parties.
In the event that Omeros is unable to make up any shortage of APIs, Hospira shall be excused from
any resulting delay in the Processing of Product but Omeros shall be bound to any firm Purchase
Orders which have been accepted by Hospira, to be completed once API becomes available. In the
event Hospira notifies Omeros that the APIs shipment does not conform to the Specifications, Omeros
shall have the right to confirm such findings at Hospira’s manufacturing location. If Omeros
determines that such shipment of APIs conformed to the Specifications, the parties shall submit
samples of such shipment to a mutually acceptable independent laboratory for testing. If such
independent laboratory determines that the shipment conformed to the Specifications, Hospira shall
bear all expenses of shipping and testing such shipment samples. If Omeros or such independent
laboratory confirms that such shipment did not meet the Specifications, Omeros shall replace, at no
cost to Hospira, the portion of the APIs which does not conform to the Specifications and bear all
expenses of shipping and testing the shipment samples.

     2.6.3 API Title. Omeros shall retain title to the APIs while in Hospira’s possession and
Hospira shall assume all responsibility and risk for the safekeeping, storage and handling of APIs
delivered hereunder and accepted by Hospira.

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO
A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

9

 

     2.6.4 Replacement of API. If, due to any negligent act or omission or willful misconduct on
Hospira’s part in the examination of APIs supplied by Omeros, Product Processed
hereunder fails to conform with the Product Specifications, Hospira’s sole liability in such
case shall be limited to replacement of non-conforming Product, at no additional cost to Omeros,
with conforming Product using APIs that Hospira shall purchase from Omeros at [†]. If APIs
are lost or destroyed in connection with the Processing of Product by Hospira, Hospira’s sole
liability in such case, [†], shall be limited to replacement of such APIs with APIs that Hospira
shall purchase from Omeros at [†].

     2.6.5 API Reimbursement. [†]

     3. DELIVERY; PRODUCT ACCEPTANCE/REJECTION; FORECASTING; PAYMENT

     3.1 Delivery of Product. Omeros will arrange the transportation of Product with Omeros
approved carriers. Hospira shall provide product together with corresponding Certificates of
Analysis in accordance with the shipping and packaging instructions set forth in the Specifications
or otherwise provided in advance by Omeros and agreed to by Hospira (including any special
packaging or shipping conditions or labeling requirements), on or before the date(s) specified for
delivery in any Purchase Order. Delivery by Hospira shall be made FOB origin (U.S.) or FCA
Hospira’s facility (international) (Incoterms 2000) at the designated location(s) specified by
Hospira. All freight, handling, insurance, duties, taxes and shipping expense will be borne by
Omeros. Title to Product shall pass to Omeros upon delivery of Product to the carrier selected by
Omeros. Hospira shall be responsible for providing all quality and commercial shipping
documentation as set forth in the Specifications or as otherwise required under Applicable Laws or
by agreement of the Parties. At no additional expense to Omeros for assistance, Hospira will
cooperate with Omeros and Omeros’ carrier to arrange for transportation of Product at Omeros’
expense from the Facility to the destination(s) specified by Omeros. Risk of loss or damage to
Product and responsibility to insure shall pass to Omeros upon delivery to Omeros on Hospira’s
dock.

     3.2 Quality Control; Certificates. Hospira shall perform quality control tests to ensure that
each Batch is produced in accordance with Applicable Laws, including cGMP, and conforms to the
Specifications. All quality control test results and copies thereof shall be made available to
Omeros upon written request of Omeros. A separate quality agreement between Hospira and Omeros
(“Quality Agreement”) will be signed prior to cGMP production of the Product, so that Omeros and
Hospira may set forth certain quality responsibilities of the Parties as they relate to the
Processing of Product in connection with this Agreement. In the event of any conflict between the
Quality Agreement and this Agreement, the terms of this Agreement shall control. Any testing
performed by or on behalf of Hospira (including tests to confirm that each Batch meets the
Specifications), which shall be performed at Hospira’s sole cost and expense, may be used by Omeros
for final release of each Batch without additional testing by Omeros. Notwithstanding the
foregoing, Omeros may conduct its own release testing of each Batch, and in accordance with
Subsection 3.3 shall determine whether such Batch is conforming. Omeros (in its sole discretion)
shall determine the form and substance of any release testing information that is submitted to a
Regulatory Authority(ies). At the time of Delivery of each

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO
A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

10

 

Batch, Hospira shall send to Omeros a
signed Certificate of Analysis with respect to such Batch and a signed Certificate of Compliance
(which may be included in the Certificate of Analysis).
Upon Omeros’ request, within thirty (30) days following the Delivery of each Batch, Hospira
shall provide Omeros with properly completed copies of Batch Records for such Batch prepared in
accordance with the Specifications and Applicable Laws, unless otherwise set forth in the Quality
Agreement. Omeros shall be responsible for all shipment validation and quality control.

     3.3 Inspection; Acceptance or Rejection. All Product Processed pursuant to this Agreement
shall be received by Omeros subject to Omeros’ right to conduct inspections and performance testing
of such Product. Omeros or its designee shall examine Product Delivered hereunder promptly after
actual receipt thereof by Omeros or its designee utilizing such methodology as Omeros shall
implement from time to time in its sole discretion.

     3.3.1 Rejection. Omeros shall have thirty (30) days from the date of actual receipt by Omeros
or its designee of each shipment of Product from Hospira in which to evaluate and accept or reject
such shipment of Product. Omeros shall be permitted to reject any shipment of Product as
non-conforming if (a) Hospira fails to timely provide an accurate Certificate of Analysis and/or
truthful Certificate of Compliance, (b) Product does not meet the Specifications, or (c) Product
was not Processed in accordance with Applicable Laws, including cGMP. If Omeros does not notify
Hospira in writing of Omeros’ rejection of such shipment of Product within thirty (30) days from
the date of receipt thereof by Omeros or its designee, Omeros shall be deemed to have accepted such
shipment of Product, except that Omeros shall retain the right to revoke acceptance of Product for
a Latent Defect pursuant to Section 3.3.3.

     3.3.2 Product Quantity. If the quantity of Product produced in any Batch fails to meet the
quantity specified in the applicable Purchase Order, then the Parties shall meet to discuss in good
faith one or more possible remedies to resolve the shortage.

     3.3.3 Latent Defect. If, after Omeros’ acceptance or deemed acceptance of a shipment of
Product, Omeros discovers a Latent Defect, Omeros shall notify Hospira within thirty (30) days
after such discovery of the Latent Defect, and Omeros shall have the right to revoke acceptance of
such shipment of Product by notifying Hospira thereof in writing. Upon such notice, such shipment
of Product shall be deemed rejected hereunder and the terms of Subsections 3.3.4 and 3.4 shall
apply.

     3.3.4 Disagreement Regarding Non-Conformity. In the event Omeros rejects a shipment of
Product for non-conformance in accordance with Subsection 3.3.1 or revokes acceptance of a shipment
of Product under Subsection 3.3.3, Hospira shall have the right within thirty (30) days thereafter
to sample and re-test such shipment of Product. If Hospira (a) agrees that such shipment of
Product is non-conforming, then the terms of Subsection 3.4 shall apply, or (b) disagrees with
Omeros’ determination that such shipment of Product is non-conforming, Hospira shall so notify
Omeros in writing within such thirty (30) day period. If Hospira disagrees with Omeros’
determination that Product is non-conforming, then Hospira and Omeros shall cause an outside
testing laboratory or consultant agreeable to both of them to perform comparative tests and/or
analyses on samples of the alleged non-conforming Product. The testing laboratory’s or
consultant’s results shall be in writing and shall be final and binding, save

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO
A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

11

 

for manifest error on
the face of its report. Unless otherwise agreed to by Hospira and Omeros in writing, the costs
associated with such testing and review shall be borne by the Party against
whom the outside testing laboratory or consultant rules. The outside testing laboratory or
consultant shall be required to enter into written undertakings of confidentiality no less
burdensome than those set forth herein. Hospira shall furnish the outside testing laboratory or
consultant such instructions regarding the storage, handling and potential hazards of any Product
as are provided to or developed by Hospira by or on behalf of Omeros.

     3.4 Remedies for Non Conforming Product. In the event that Hospira agrees that a shipment of
Product is non-conforming, or if the outside testing laboratory or consultant determines that such
Product is non-conforming, then, at Omeros’ election, Hospira shall [†]. Upon Hospira’s
instructions, Omeros shall destroy or return, at Hospira’s cost, the non-conforming Product.

     3.5 Custody of Omeros Property. In connection with this Agreement, the Parties agree that
Hospira will have custody over certain Omeros Property. It is understood that such Omeros
Property, to the extent practicable, will be clearly labeled by Hospira as belonging to Omeros, and
that Hospira shall bear the risk of loss for any Omeros Property during the time that such Omeros
Property is in the possession of Hospira. Title to Omeros Property shall at all times remain in
Omeros or its assigns, and Hospira shall not pledge to any third party a security or other interest
in the Omeros Property, nor shall Hospira allow the Omeros Property to be otherwise encumbered.
Hospira shall at all times employ the measures specified by Omeros, and take such measures as are
otherwise reasonably required, to protect Omeros Property from risk of loss or damage at all stages
of Processing the Product and the Services hereunder. Hospira shall immediately notify Omeros if
at any time it believes any Omeros Property has been damaged, lost or stolen. Hospira shall not
use any Omeros Property for any purpose other than performing its obligations under this Agreement.
Upon any request by Omeros, Hospira shall immediately return to Omeros all Omeros Property,
including all copies thereof, in conformance with any directions provided by Omeros therefore,
except that Hospira shall retain reserve samples of Product as provided in Subsection 3.6.

     3.6 Retention Samples; Storage. Hospira shall retain and store, in accordance with the
Specifications, samples of each Batch of Product at the Facility at no cost to Omeros until the
date that is thirteen (13) months after the expiration date of each such Batch (or for such longer
period as may be required by applicable Regulatory Authorities or Applicable Laws). Thereafter, if
requested by Omeros, Hospira and Omeros shall negotiate in good faith and enter into a contract for
continued storage of such Product samples, at Omeros’ reasonable cost and expense; provided,
however, that at any time following the initial storage period set forth above, if Hospira decides
that it will no longer store such samples or Omeros decides it does not wish to continue to have
Hospira store such samples, such Party shall provide no less than sixty (60) days’ written notice
to the other Party, during which time Omeros will instruct Hospira to either return such samples to
Omeros or a third party designated by Omeros, or to destroy such samples. Hospira shall comply
with such instructions from Omeros, provided that Omeros shall reimburse Hospira its reasonable
out-of-pocket costs incurred in returning or destroying such samples.

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO
A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

12

 

     3.7 Marketed Product Stability Samples. Hospira shall, in accordance with SOPs, pull
stability samples of Product and either (a) retain, store and test such stability samples in
accordance with the Specifications, or (b) ship such stability samples to Omeros or a third
party designated by Omeros in accordance with the Specifications. Hospira shall provide Omeros at
least sixty (60) days advance written notice prior to disposition of any stability samples after
specified storage times have elapsed, and Omeros shall provide instructions on disposal, continued
storage or shipment of such samples at Omeros’ reasonable expense. Upon Omeros’ written request,
Hospira shall provide stability testing of the Product in accordance with ICH guidance at a total
cost of [†] (the “Stability Lot Price”) put up on stability testing in accordance with a time point
matrix to be mutually agreed in writing and, upon such agreement, appended and incorporated into
this Agreement as Exhibit C.. The Stability Lot Price shall be invoiced on a pro-rata basis for
each stability time point completed. The Stability Lot Price is based on an assumed shelf life of
[†], and should the shelf life increase or decrease the Stability Lot Price shall be adjusted
proportionately.

     3.8 Price; Adjustments; Payment

     3.8.1 Initial Product Pricing. Hospira shall invoice Omeros upon shipment of Product by
Hospira, at the Price [†] of Product set forth in Exhibit B of this Agreement.

     3.8.2 Price Adjustments. [†].

     3.8.3 Payment Terms. [†]. Omeros shall make payment of any undisputed portion of such
invoices within [†] after Omeros’ receipt of each such invoice, unless otherwise specifically set
forth in this Agreement. If Omeros should default on any undisputed, due and owing payment,
interest shall accrue on any undisputed amount that is overdue at the rate of [†] per month or the
maximum rate allowed by law, whichever is lower.

     3.9 Product Forecasts.

     3.9.1 Rolling [†] Estimate. No later than [†], Omeros shall provide Hospira with a written
estimate of Omeros’ [†] quantity of commercial Product that represents the Minimum Percentage of
Omeros’ Product Requirements for the first [†] of the Term, such estimate to be used by Hospira
solely for [†] planning purposes. Omeros shall not incur any liabilities if such estimate is not
met. If Hospira notifies Omeros (and such notification shall be provided to Omeros in writing)
that it will be unable to supply Product in accordance with Omeros’ estimate, Omeros shall have the
right, in its sole discretion, [†]. Thereafter, by
[†], Omeros shall update such rolling [†]
estimate (“Rolling [†] Estimate”) for the period commencing on [†]. Upon receipt of each Rolling
[†] Estimate, Hospira shall, within [†] days after such receipt, provide Omeros a written (a)
acceptance of such estimate (and in such event, Hospira shall plan to allocate its capacity in a
manner consistent with such Rolling [†] Estimate), or (b) rejection of such estimate. In the event
Hospira rejects any updated Rolling [†] Estimate, Hospira and Omeros shall meet as soon as possible
to discuss in good faith the quantities of Product that Hospira would have capacity to provide to
Omeros during [†] covered by the Rolling [†] Estimate, and any amount agreed to shall be
memorialized by the Parties in writing in a revised Rolling [†] Estimate. In such event and in
Omeros’ discretion, Omeros shall have the right to [†].

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO
A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

13

 

     3.9.2 Notification and Rolling Forecast. Omeros will provide Hospira with written notice when
a new drug application (“NDA”) to market Product is submitted to FDA. Hospira
and Omeros will cooperate in scheduling and estimating initial commercial Batches of the
Product. On or before the first (1st) day of each calendar month, beginning at least
[†] prior to the anticipated date of commencement of commercial manufacture (excluding process
validation batches), Omeros shall provide to Hospira an [†] rolling forecast of the quantities of
Product that Omeros intends to order from Hospira during such period (“Rolling Forecast”). The
first [†] of such Rolling Forecast shall constitute a binding order of Omeros and a supply
commitment of Hospira for the quantities of Product specified therein (“Firm Commitment”), and the
following [†] of the Rolling Forecast shall be a good faith estimate, the [†] of such [†] period
which is binding to the extent set forth in the Supply and Purchase Commitment described in Section
3.10.4 below.

     3.10 Purchase Orders; Supply and Purchase Commitment.

     3.10.1 Purchase Orders. On or before the first (1st) day of each calendar month,
Omeros shall submit a purchase order (each a “Purchase Order”) to Hospira covering Omeros’
purchases of Product pursuant to the [†] of the Firm Commitment that is effective as of such first
day, and shall specify the Delivery dates for the Product included in such Purchase Order. Hospira
will use commercially reasonable good faith efforts to accept and meet the Delivery date specified
by Omeros in the Purchase Order. Omeros shall not, without the written consent of Hospira,
designate a Product Delivery date in a Purchase Order that is earlier than [†]calendar days from
the date on which Omeros submits the Purchase Order. For each Purchase Order, Hospira shall
provide (a) a confirmation of acceptance of the Purchase Order based on the Product Delivery date
specified by Omeros, or (b) a proposed modification of the Purchase Order offering to accept the
Purchase Order based on an alternate Product Delivery date. Upon (a) Omeros’ receipt of Hospira’s
confirmation of acceptance of the unchanged Purchase Order, or (b) Hospira’s receipt of Omeros’
written confirmation accepting the modified Purchase Order with the alternate Product Delivery
date, such Purchase Order shall become a “Firm Purchase Order.” If Hospira subsequently finds that
it is unable to meet the specified Product Delivery date for a Firm Purchase Order, Hospira shall
promptly notify Omeros and provide to Omeros an alternative Product Delivery date (which shall not
be more than fifteen (15) calendar days later than the initial Product Delivery date designated in
the Firm Purchase Order).

     3.10.2 Purchase Order Changes. In the event that Omeros requests any change to the Delivery
date set forth in a Firm Purchase Order, Hospira shall attempt to accommodate the Delivery date
change within reasonable manufacturing capabilities and efficiencies. [†]. Hospira shall also
advise Omeros of the reasonable costs associated with making any such Delivery date change (if
any), and Omeros shall be deemed to have accepted the obligation to pay Hospira for such
associated, reasonable costs if Omeros indicates in writing to Hospira that Hospira should proceed
to make the change. Hospira shall charge Omeros the amount agreed upon in writing by Omeros for
making any such Delivery date change. If Omeros cancels a Firm Purchase Order, Hospira shall be
relieved of its obligation relating to such order, but Omeros will not be relieved of its
obligation of payment unless Hospira agrees to such cancellation in writing [†]. Subject to
Hospira’s compliance with the terms of Section 2.6.4, if Omeros (a) does not supply sufficient API
to Process Product in accordance with a given Firm Purchase Order, or (b) acts in any other

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO
A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

14

 

manner, not including any change requested by Omeros due to changes in regulatory or other Applicable Law
or to ensure that the Product meets the Specifications, to directly and effectively
interfere with Hospira’s ability to perform in accordance with a given Firm Purchase, Omeros
shall remain liable for the full amount of the Firm Purchase Order, regardless of whether such
Product is Processed by Hospira or whether Omeros takes Delivery of any such Processed Product [†].
Notwithstanding the foregoing, Hospira shall use its commercially reasonable efforts to supply
Omeros with quantities of Product which are in excess of the quantities specified in a Firm
Purchase Order, subject to Hospira’s other supply commitments and manufacturing and equipment
capacity.

     3.10.3 Agreement Controls. In the event of a conflict between the terms of any Firm Purchase
Order and this Agreement, this Agreement shall control.

     3.10.4 Supply and Purchase Commitment. Hospira shall supply Omeros with the quantity of
Product ordered by Omeros in each Firm Purchase Order, unless the quantity of Product ordered for
any calendar quarter exceeds [†] thereafter, in which event Hospira shall use commercially
reasonable efforts to supply quantities in excess of these amounts.

     3.10.5 Purchase Commitment. Following completion of the first [†] of the Initial Term, Omeros
covenants to purchase from Hospira not less than [†]  of the Rolling Forecast
during the [†] of the Initial Term thereafter (the “Minimum Purchase Requirement”). Omeros may
shift any portion of its Firm Commitment to the [†] of the Rolling Forecast so long as its Minimum
Purchase Requirement is met. In lieu of Omeros taking Delivery of each such [†] Minimum Purchase
Requirements of Product, Omeros shall have the option, to be exercised in writing if elected by
Omeros, to pay for its Minimum Purchase Requirement at the Price set forth in Exhibit B and
waive Hospira’s Processing and Delivery obligations for the corresponding amount of Product. In
the latter event, Hospira shall invoice Omeros for the amount payable to meet the Minimum Purchase
Requirement, and Omeros shall pay Hospira such amount within [†] after receipt of Hospira’s
invoice.

     3.10.6 Failure/Inability to Supply.

(a) At Least [†]. If Hospira fails to, or is unable to, supply Omeros with at least [†]
of the quantity of Product ordered by Omeros pursuant to the greater of (i) all Firm Purchase
Orders received during [†], or (ii) Omeros’ Firm Commitment for any [†].

(b) At Least [†]. If Hospira fails to, or is unable to, supply Omeros with at least [†]
of the quantity of Product ordered by Omeros pursuant to the greater of (i) all Firm Purchase
Orders received during [†], or (ii) Omeros’ Firm Commitment for any [†], then promptly thereafter
Hospira’s and Omeros’ senior executives shall meet to develop a corrective action plan and/or
remedy. If such mutually acceptable corrective action plan and/or remedy is not developed and
mutually agreed [†] after the first meeting of such executives, then Omeros shall have the right,
in its sole discretion, to either [†].

     3.11 Rework. Hospira will not rework or reprocess Product unless authorized in advance by
Omeros in writing and there is a validated process for such rework or reprocessing of Product.
Re-inspection does not constitute rework or reprocessing.

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO
A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

15

 

     3.12 Product Recalls. In the event that any Product is recalled due to (a) the request,
directive or order of any Regulatory Authority or other national government authority, (b) the
order of a court of competent jurisdiction, or (c) a voluntary recall instituted by Omeros, Omeros
shall coordinate such recall, and the Parties shall take all appropriate actions to carry out such
recall and shall cooperate with any governmental investigations surrounding such recall. The cost
of any such recall shall be borne by Hospira if the recall results from the failure of the Product
to meet Specifications or Hospira’s breach of this Agreement,
including, without limitation, breach of Hospira's warranties under
Section 4.1 of this Agreement [†]. Further, Hospira shall at
Hospira’s expense, replace any recalled Batches and shall purchase replacement APIs or other
Materials from Omeros for such replacement Product at Omeros purchase cost/kg as set forth in
Section 2.6.3; [†]. The cost of any other recall shall be borne exclusively by Omeros. For
purposes of this Agreement, recall expenses shall include, without limitation, the expenses of
notification and destruction or return of the recalled Product, cost of the recalled Product, and
any costs associated with the APIs and other Materials for and Processing and distribution of
replacement Product, but shall not include lost profits of either Party.

     3.13 Hazardous Waste. Hospira shall be responsible for destruction of any and all hazardous
waste, including, without limitation, rejected or recalled Product, rejected, excess or unsuitable
APIs or other Materials, remainder, residue and refuse, subject first to completion of any
retention periods and activities specified in this Agreement, in accordance with the Applicable
Laws. Omeros shall bear the expense of destruction of hazardous waste, except for any hazardous
waste resulting from Hospira’s breach of this Agreement, including, without limitation, breach of
any warranty under Section 4.1 herein, for which hazardous waste Hospira shall bear the expense.

     3.14 Cold Storage Fee. A cold storage fee shall be due and payable to Hospira if Omeros
stores Product at Hospira’s plant for longer than thirty (30) days after Product’s final release.
The fee shall be [†] or any part thereof.

     3.15 Shipments per Batch. Hospira shall make [†] shipments to Omeros of Product per Batch at
no charge to Omeros. Any additional shipments of Product per Batch requested shall be at a fee of
[†] per shipment plus shipping costs.

     4. REPRESENTATIONS AND WARRANTIES

     4.1 Hospira Representations and Warranties. Hospira represents and warrants that: (a) it has
the full power, right and authority to execute and deliver this Agreement; (b) it shall use
commercially reasonable best efforts to perform its obligations hereunder; (c) it will assign
professional personnel, qualified to perform the Services in a manner consistent with the technical
requirements of the Processing of Product; (d) none of its officers, directors, employees,
Affiliates, contractors or agents has been debarred or, to Hospira’s knowledge, threatened with
debarment under the Generic Drug Enforcement Act or convicted of a crime which could lead to
debarment, and it has not utilized, and will not utilize, the services of any individual or entity
in the performance of any Services that has been debarred or threatened with debarment under the
Generic Drug Enforcement Act, convicted of a crime that could lead to debarment or subject to any
other penalty or sanction by the FDA; (e) it will conduct the Services in conformity with
Applicable Laws including applicable cGMP, the procedures and

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO
A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

16

 

parameters set forth in the Specifications, and generally accepted professional standards, and
the event of any conflicts between the foregoing requirements, the most stringent requirement shall
be met so long as consistent with all Applicable Laws; (f) each Certificate of Analysis will
reflect the results of the tests conducted on the Batch of Product to which it relates, each
Certificate of Compliance will be accurate and true, and the Batch Records delivered to Omeros will
accurately reflect in all material respects the processes and procedures followed by Hospira in
Processing Product as set forth in the Specifications; (g) the Product shall not have been and
shall not be adulterated, misbranded, misused, contaminated, tampered with or otherwise altered,
mishandled while in the custody and control of Hospira; and (h) it will not transfer to any third
party any Product, other than (i) for the purpose of tests at any outside testing laboratory or
consultant, as provided under Subsection 3.3.4, (ii) to Omeros’ designee or (iii) to any
subcontractor approved in accordance with Subsection 6.1. In the event that Hospira receives
notice of the debarment or threatened debarment of any individual or entity utilized by Hospira in
connection with the Product, Hospira shall notify Omeros in writing immediately, and Omeros shall
have the right to terminate this Agreement upon written notice without further cost or liability,
except for payments of accrued and unpaid obligations to the date of termination. Hospira further
represents and warrants that it has obtained (or will obtain prior to Processing Product or
performance of other Services), and will remain in compliance with during the term of this
Agreement, all permits, licenses and other authorizations which are required under Applicable Laws
for the Processing of Product or performance of other Services hereunder.

     4.2 Mutual Representations and Warranties. Each Party hereby represents and warrants to the
other Party that: (a) the person executing this Agreement is authorized to execute this Agreement;
(b) this Agreement is legal and valid and the obligations binding upon such Party are enforceable
by their terms; and (c) the execution, delivery and performance of this Agreement does not conflict
with any agreement, instrument or understanding, oral or written, to which such Party may be bound,
nor violate any law or regulation of any court, governmental body or administrative or other agency
having jurisdiction over it.

     4.3 Omeros Representations and Warranties. Omeros represents and warrants:
(a) if Omeros supplies APIs to Hospira for use in Processing the Product, then all such
Omeros’ supplied API at the time of delivery to Hospira shall be in conformity with the applicable
Specifications and shall not be adulterated or misbranded within the meaning of the Act; (b)
Hospira’s Processing of Product and performance of the Services pursuant to the Specifications will
not, to Omeros’ knowledge, violate any third party proprietary right; and (c) Omeros will not sell
Product into any jurisdiction unless and until Omeros receives any necessary Regulatory Authority
approvals.

     5. RECORDS; REGULATORY MATTERS

     5.1 Technical Records. Hospira shall maintain complete, true and accurate Technical Records
in accordance with Applicable Laws and as is reasonably necessary to support Omeros’ regulatory
filings with respect to Product. Hospira shall store all Technical Records for the longer of a
period of at least [†] from the relevant Product manufacturing date or the period required under
Applicable Laws, after which Hospira may dispose of the Technical Records or return the Technical
Records (excluding General SOPs and any Confidential

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO
A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

17

 

Information of Hospira) to Omeros in accordance with Omeros’ express written instructions
therefore. In the absence of such instructions, Hospira shall notify Omeros in writing of its
intent to dispose of the Technical Records and request Omeros’ instructions as to their disposal.
If Omeros does not respond to such notice within sixty (60) days after receipt thereof, or in any
event prior to the later destruction of such records, Hospira may destroy such records at its
discretion and expense. Hospira shall, at any time upon Omeros’ written request and at Omeros’
reasonable expense, return the Technical Records to Omeros or transfer the Technical Records to any
third party designated by Omeros.

     5.2 Drug Master File; Regulatory Filings. Hospira shall file and maintain the appropriate
drug master file (“DMF”) and related reference applications (e.g., site master file) in accordance
with the Applicable Laws in the Territory for its Processing of each Product under this Agreement,
at Hospira’s sole expense. Upon request by Omeros, Hospira shall make selected portions (including
all portions relevant to the Processing of the Product) of its DMF and related reference
applications, and all Technical Records available for inspection by authorized representatives of
the FDA and other Regulatory Authorities. At Omeros’ request and as agreed upon by Hospira,
Hospira shall prepare some or all sections of Omeros’ regulatory filings (including without
limitation chemistry, manufacturing and control sections) for a Product that pertain to Hospira’s
Processing activities hereunder, or at Omeros’ request shall assist Omeros in preparing such
sections; provided that Omeros shall compensate Hospira for its reasonable out-of-pocket costs and
expenses associated with such preparation activities. Hospira shall provide any additional
information, and otherwise cooperate as reasonably requested by Omeros, at Omeros’ reasonable cost
and expense, in support of any regulatory filings related to Product, including in the preparation
and maintenance of such regulatory filings, which regulatory filings shall be filed by Omeros at
its sole cost and expense in its sole discretion and shall be the sole and exclusive property of
Omeros.

     5.3 Communications with Regulatory Authorities. Omeros shall be solely responsible for all
contacts and communications with any Regulatory Authority with respect to all matters relating to
Product. At Omeros’ request and expense, Hospira shall make appropriate personnel reasonably
available for meetings with Regulatory Authorities related to Hospira’s Processing of Product or
other Services. Other than during an audit or inspection by any Regulatory Authority, Hospira
shall have no contact or communication with any Regulatory Authority regarding a Product or
regarding Hospira’s Processing activities or other Services related to Product without the prior
written consent of Omeros, which consent may be granted or withheld in Omeros’ sole discretion,
except as provided in Subsection 5.6 or as required by Applicable Law or a Regulatory Authority.
Hospira shall notify Omeros immediately, and in no event later than two (2) business days, after
receiving any contact or communication from any Regulatory Authority that in any way directly
relates to Product or Hospira’s Processing activities or other Services.

     5.4 Compliance. Hospira shall comply in all material respects with all regulatory
requirements with respect to Product that are imposed upon Hospira (as the provider of Services
hereunder) by Applicable Law from time to time, including, but not limited to, those relating to
environmental, health, and safety matters. Omeros shall comply in all material respects with all
regulatory requirements with respect to Product that are imposed upon Omeros (as the holder of

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO
A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

18

 

any Investigational New Drug application or New Drug Application and any similar global
applications with respect to Product) by Applicable Law from time to time.

     5.5 Audits; Right of Access. Hospira shall permit Omeros personnel and authorized
representative(s), or shall ensure that Omeros personnel and authorized representative(s) shall be
entitled (a) to inspect, observe and audit the Processing of Product and other Services, the
Facility and any other locations at which Product may be Processed with Omeros’ consent, (b) to
examine the condition of the Materials, Omeros Property, and Product stored at the Facility, and
(c) to examine all Product Data, Technical Records and all other documentation related to this
Agreement, including, without limitation, maintenance logs for the purposes of ensuring compliance
with cGMP and Hospira’s trade secrets and other Confidential Information related to its
manufacturing processes to the extent relevant to the Processing of Product and/or other Services
performed by Hospira hereunder, not to exceed [†] (except “for cause” audits as set forth below in
this Subsection) during the term of this Agreement, subject to reasonable notice and prior approval
by Hospira, such approval not to be unreasonably withheld, during regular business hours, and for a
period not to exceed [†]; provided that such Omeros personnel and/or authorized representative(s)
shall be bound to obligations of confidentiality pursuant to this Agreement or pursuant to a
separate, executed confidentiality agreement that imposes an obligation of confidentiality no less
onerous than the obligation imposed pursuant to Section 8 of this Agreement. Notwithstanding these
limitations, Omeros personnel and/or representatives shall be entitled to observe the Processing of
Product and other Services at any time upon reasonable notice and for a reasonable duration during
regular business hours (including during any shift that is engaged in Processing of Product or
performance of other Services). Omeros shall be entitled to conduct “for cause” audits following
issuance of Form 483s or similar reports delivered by Regulatory Authorities to Hospira pertaining
to the Processing of Product, performance of other Services, or the occurrence of other events
which are likely to adversely affect the Processing of Product or other Services as frequently as
requested by Omeros at reasonable times and for reasonable duration (which may exceed [†] days)
until Hospira has corrected such deficiencies, subject to Hospira approval, such approval not to be
unreasonably withheld. Hospira shall audit its permitted subcontractors and suppliers for
compliance with the Specifications and Applicable Laws, including cGMP according to Hospira’s
standard subcontractor audit procedures, if the subcontractors are chosen by Hospira. Omeros shall
be responsible for audit of all subcontractors and suppliers that have been selected by Omeros in
lieu of subcontractors and suppliers recommended or routinely used by Hospira. During Omeros’
audits of the Facility, Omeros shall have the right to confirm Hospira’s compliance with Hospira’s
standard operating procedures for auditing subcontractors and suppliers for any Products Processed
or other Services performed under this Agreement.

     5.6 Regulatory Inspections. Hospira shall advise Omeros no later than the next day that is
not a Saturday, Sunday or federal or state holiday if an authorized agent of any Regulatory
Authority or any other regulatory body plans to visit the Facility, and makes an inquiry regarding
Hospira’s Processing of Product or performance of other Services regarding any part of the Facility
that is used in Processing of Product or performance of other Services. Omeros shall have the
right to be present at any visit directly relating to the Product or otherwise with Hospira’s
approval, which approval shall not be unreasonably withheld, and to review in advance and comment
on any response to the communication or investigation submitted by

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO
A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

19

 

Hospira (but no more than [†] Omeros personnel shall be present during any such visit).
Hospira shall cooperate fully with Omeros in providing the information needed for any such
communication. Hospira shall provide to Omeros copies of any Form 483s or equivalent documents
delivered by such Regulatory Authority or regulatory body as a result of such visit, to the extent
that the 483 or other document specifically mentions Product. Portions of the 483 or other
document not relating to Product will be redacted.

     5.7 Product Complaints. Omeros shall maintain customer complaint and adverse event files in
accordance with Applicable Laws. Any such complaints received by Hospira shall be forwarded to
Omeros. Omeros shall be responsible for the review of the complaint or adverse event to determine
the need for an investigation or the need to report to the FDA, as required by Applicable Laws.
Omeros shall provide Hospira copies of all Product performance or manufacturing-related complaints
that relate directly to Processing of Product by Hospira and require investigation, as well as
copies of the results of such investigation. Hospira shall cooperate and assist Omeros in any such
investigations and shall fully report findings of any investigation it conducts to Omeros. Omeros
shall make specific complaint and adverse event files available for inspection, to the extent
required by any Regulatory Authority, during inspection of Hospira’s facilities.

     5.8 Hospira Right to Review. Hospira shall have the right to review and consult on those
portions of Omeros’ proposed regulatory submissions relating to Hospira’s Processing procedures
before any submissions are filed with appropriate Regulatory Authorities. Omeros shall use
commercially reasonable efforts to provide Hospira with no less than fifteen (15) business days to
review any such proposed regulatory submissions and Hospira will use commercially reasonable
efforts to expedite any review. Omeros shall provide copies and consult with Hospira and Hospira
may advise Omeros in responding to questions from the Regulatory Authorities regarding Omeros’
submission(s) for Product. Omeros shall provide to Hospira for its files a final copy of the
Chemistry, Manufacturing and Controls section of any such regulatory submission(s) related to
Hospira’s Processing.

     6. SUBCONTRACTORS

     6.1 Conditions. [†] Hospira shall be responsible, and shall remain liable, for the
performance of all of its obligations under this Agreement and for any breach by any subcontractor.
Omeros shall have the right to audit and inspect all subcontractors (including, without
limitation, all vendors and testing contractors) with whom Hospira may enter into agreements in the
performance of Services. Such audit and inspection rights shall be substantially similar to the
rights of Omeros to audit and inspect Hospira under this Agreement. Hospira shall ensure that all
agreements with such subcontractors include provisions to maintain the confidentiality of Omeros’
Confidential Information, and shall provide Omeros rights with respect to such subcontractors that
are substantially similar to the access rights granted to Omeros under Subsection 5.5 above.

     7. INTELLECTUAL PROPERTY

     7.1 Ownership of Intellectual Property. Except as expressly set forth in this Agreement or as
the Parties may otherwise agree in writing, each Party owns, and shall continue

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO
A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

20

 

to own, its existing Intellectual Property as of the Effective Date of this Agreement, and its
Intellectual Property developed, acquired or obtained by such Party after the Effective Date of
this Agreement independently of the other Party and the Services, without conferring any interest
therein on the other Party. [†] The parties recognize that Hospira is in the business of
developing, manufacturing, and selling generic pharmaceutical products.  Nothing in this provision
is intended to prohibit Hospira from independently developing, manufacturing, and/or selling any
pharmaceutical product provided that Hospira does not utilize, refer to, and/or rely upon any [†]
in the development, manufacturing, and/or sale of such product in contravention of the exclusive
license granted to Omeros herein. The preceding sentence does not in any way convey to Hospira any
right or license to Omeros’ Intellectual Property, including without limitation the New Omeros IP,
or to Omeros’ Confidential Information, or limit Hospira’s obligations with respect to the same as
provided in this Agreement.

     7.2 License to Hospira. During the Term, Omeros hereby grants to Hospira a royalty-free,
non-exclusive license, without a right to sublicense, to use and exploit Intellectual Property
owned by or licensed to Omeros and used in connection with the Processing of Product, solely to the
extent necessary to Process Product for Omeros under the terms and conditions of this Agreement.

     7.3 Product Data. All Product Data, including, without limitation, all Batch Records and
other Product-specific Technical Records generated or obtained by Hospira in connection with this
Agreement, and all Specifications, including, without limitation, Master Batch Records generated or
obtained by Hospira in connection with this Agreement, but excluding General SOPs, shall be the
sole and exclusive property of Omeros and shall be deemed to be Omeros’ Confidential Information.
Upon expiration or termination of this Agreement or the earlier request of Omeros, Hospira shall
send to Omeros at Omeros’ sole and reasonable expense, complete copies of all Product Data and
Specifications in written and (where available) editable electronic form. The Product Data shall
be prepared, documented and communicated by Hospira in a manner consistent with the Specifications
or as otherwise instructed by Omeros.

     7.4 No Implied Right or License. Nothing contained in this Agreement shall be implied to
grant to either Party any right or license with respect to the other Party’s Intellectual Property
or Confidential Information of the other Party, except as specifically provided in this Agreement.

     8. CONFIDENTIALITY

     8.1 Confidential Information. Each Party agrees that the disclosing Party has and shall
retain sole and exclusive rights of ownership in all Confidential Information disclosed or owned by
such Party. Each Recipient agrees that during the term of this Agreement and for [†] thereafter it
will not use any Confidential Information of the disclosing Party except for the purposes of
performing under this Agreement, unless otherwise agreed by the Parties in writing. Each Recipient
agrees not to disclose any Confidential Information of the disclosing Party to others (except to
Recipient’s employees, consultants, professional advisors, agents and Affiliates who reasonably
require disclosure of such Confidential Information to achieve the purposes of this Agreement and
who are bound to the Recipient by like obligations as to confidentiality no

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO
A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

21

 

less stringent than those set forth herein) during the term of this Agreement and for [†]
thereafter without the prior written consent of the disclosing Party. Hospira agrees that with
respect to the Product Data, the Specifications and the Omeros New IP, which are included in
Omeros’ Confidential Information, these obligations of non-use and confidentiality shall subsist
beyond five years after the termination of this Agreement. Each Party agrees to maintain and
follow reasonable procedures to prevent unauthorized disclosure or use of the other Party’s
Confidential Information and to prevent it from becoming disclosed or being accessed by
unauthorized persons. Each Party agrees that it may disclose to authorized persons only such
Confidential Information of the disclosing Party as is necessary for each such authorized person to
perform its responsibilities under this Agreement. Recipient shall advise the disclosing Party of
any disclosure, loss, or use of Confidential Information of the disclosing Party in violation of
this Agreement as soon as practicable. Each Party agrees to return or destroy the Confidential
Information of the other Party, whether in written, graphic, electronic or other tangible form,
upon written request, provided, however, that legal counsel for each Party may retain an archival
copy of Confidential Information solely for purposes of ensuring compliance with this Agreement.

     8.2 Disclosure of this Agreement. The terms of this Agreement shall be considered each
Party’s Confidential Information, and accordingly except for disclosures expressly permitted under
this Agreement, neither Party may release any information to any third party regarding the terms of
this Agreement without the prior written consent of the other Party except as required by law or
regulation. Notwithstanding the foregoing, the terms of this Agreement may be disclosed by Omeros
to its existing or potential investors, acquirers, merger partners, commercial partners,
shareholders, directors and professional advisors as long as such parties are subject to similar
conditions of confidentiality.

     8.3 Permitted Disclosures. Notwithstanding anything to the contrary, a Party may disclose the
Confidential Information of the other Party only to the extent such disclosure is reasonably
necessary : (a) to secure patent protection for an Intellectual Property developed pursuant to this
Agreement consistent with the ownership set forth in Subsection 7.1; or (b) to comply with
Applicable Law, requirements of any Regulatory Authority or other regulatory or governmental
agency, including without limitation the FDA, the Securities and Exchange Commission, the Federal
Trade Commission and/or the Department of Justice, or judicial order from a court of competent
jurisdiction; or (c) in order to conduct pre-clinical or clinical trials or seek regulatory
approval to market Product. Prior to making any such permitted disclosures, however, the
disclosing Party shall give reasonable advance notice to other Party with as much detail as
possible in relation to the disclosure. Each Party agrees that it shall cooperate fully and in a
timely manner with the other Party with respect to all such permitted disclosures, including
determining what information should be released and requests for confidential treatment of
Confidential Information of either Party included in any such disclosure; provided that in no event
shall a Party be required to delay any filing or release unreasonably hereunder.

     8.4 Remedies. Because of the unique nature of the Confidential Information, each Recipient
acknowledges and agrees that the disclosing Party may suffer irreparable injury if the Recipient
fails to comply with the obligations set forth in this Section 8, and that monetary damages may be
inadequate to compensate the disclosing Party for such breach. Accordingly,

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO
A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

22

 

each Recipient agrees that the disclosing Party will, in addition to any other remedies
available to it at law, in equity or otherwise, without the requirement to post a bond, be entitled
to seek injunctive relief and/or specific performance to enforce the terms, or prevent or remedy
the violation, of this Section 8. This provision shall not constitute a waiver by either Party of
any rights to damages or other remedies which it may have pursuant to this Agreement or otherwise.

	 	9.	 	NO WARRANTY; LIMITATION OF LIABILITY; INDEMNIFICATION; INSURANCE

     9.1 No Warranty; Limitation of Liability. EXCEPT AS EXPRESSLY SET FORTH HEREIN, EACH
PARTY DISCLAIMS ALL CONDITIONS, REPRESENTATIONS AND WARRANTIES, WHETHER EXPRESS, IMPLIED, STATUTORY
OR OTHERWISE, INCLUDING, WITHOUT LIMITATION, ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR
A PARTICULAR PURPOSE OTHER THAN THAT THE PRODUCT MEETS THE SPECIFICATIONS, OR ANY WARRANTY OF
NON-INFRINGEMENT OF THIRD PARTY RIGHTS. UNDER NO CIRCUMSTANCES SHALL EITHER PARTY, ANY OF ITS
AFFILIATES OR ANY OF THEIR RESPECTIVE DIRECTORS, OFFICERS, EMPLOYEES, REPRESENTATIVES, AGENTS,
LICENSORS OR PARTNERS BE LIABLE FOR ANY SPECIAL, INDIRECT, INCIDENTAL, EXEMPLARY, CONSEQUENTIAL OR
PUNITIVE DAMAGES OR LIABILITIES (INCLUDING, WITHOUT LIMITATION, SUCH DAMAGES OR LIABILITIES FOR
LOSS OF PROFITS, BUSINESS, USE OR OTHER ECONOMIC ADVANTAGE) ARISING OUT OF OR IN ANY WAY RELATED TO
THIS AGREEMENT (INCLUDING PERFORMANCE OR FAILURE TO PERFORM HEREUNDER), EVEN IF SUCH PARTY HAS BEEN
ADVISED OF THE POSSIBILITY THEREOF, AND REGARDLESS OF THE LEGAL OR EQUITABLE THEORY (CONTRACT,
TORT, OR OTHERWISE).

     9.2 Omeros’ Indemnification. Omeros shall indemnify, defend and hold harmless Hospira and its
officers, employees and agents (collectively, the “Hospira Indemnitees”) from and against any and
all liabilities, obligations, penalties, claims, judgments, demands, suits, costs and expenses
(including, without limitation, reasonable attorneys’ fees) (any of the foregoing, “Damages”)
arising out of or occurring as a result of a claim or demand made by an unaffiliated third party
against a Hospira Indemnitee for property damage or personal injury (including, without limitation,
death), in connection with: (a) Omeros’ storage, promotion, labeling, marketing, distribution, use
or sale of Product; (b) Omeros’ negligence, wrongful act or willful misconduct; (c) any breach by
Omeros of its obligations, representations, warranties or covenants under this Agreement; (d) the
lack of safety or efficacy of the APIs or Product; or (e) any violation of any patent or
proprietary right of any third party relating to the APIs, Specifications or Product other than
Hospira’s General SOPs or other Hospira developed Development or Processing procedures used in the
Processing of Product pursuant to this Agreement, except to the extent that any such Damages are
caused by (i) any failure of the Product to meet the Specifications or any Latent Defect in the
Product caused by a Hospira Indemnitee, (ii) the gross negligence or willful misconduct of a
Hospira Indemnitee, (iii) by the breach by a Hospira Indemnitee of its obligations,
representations, warranties or covenants under this Agreement, including, without limitation,
failure to comply with the Specifications or any Applicable Laws, (iv) by the violation of any
patent or proprietary Intellectual Property

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO
A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

23

 

right of any third party that was known to Hospira and was not known to Omeros at the time of
such violation, (v) the purchase, transportation, storage, use, handling or disposal of any
hazardous substances in connection with performance of the Services by a Hospira Indemnitee, or
(vi) any claim that the Processing or performance of Services by a Hospira Indemnitee pursuant to
Hospira’s General SOPs or other Hospira developed Development or Processing procedures violates a
proprietary Intellectual Property right of any third party (except to the extent that such claim
results from the Specifications or other instructions or directions from Omeros).

     9.3 Hospira’s Indemnification. Hospira shall indemnify, defend and hold harmless Omeros and
its officers, employees, and agents (collectively, the “Omeros Indemnitees”), from and against any
and all Damages arising out of or occurring as a result of a claim or demand made by an
unaffiliated third party against an Omeros Indemnitee for property damage or personal injury
(including, without limitation, death) in connection with: (a) Hospira’s negligence or willful
misconduct; (b) any failure of the Product to meet the Specifications, any Latent Defect in the
Product caused by Hospira; (c) any breach by Hospira of its obligations, representations,
warranties or covenants under this Agreement, including, without limitation, Hospira’s failure to
comply with the Specifications or any breach by Hospira of the Applicable Laws; (d) Hospira’s
purchase, transportation, storage, use, handling or disposal of any hazardous substances in
connection with performance of the Services; or (e) any claim that the Processing or performance of
Services by Hospira pursuant to Hospira’s General SOPs or other Hospira developed Development or
Processing procedures violates a proprietary Intellectual Property right of any third party (except
to the extent that such claim results from the Specifications or other instructions or directions
from Omeros), except to the extent that any such Damages are caused by; (i) the gross negligence or
willful misconduct of an Omeros Indemnitee, or (ii) by the breach by an Omeros Indemnitee of its
obligations, representations, warranties or covenants under this Agreement.

     9.4 Procedure. In the event that any third party claim, action or suit is instituted against
a Party (the “Indemnified Party”) or its employees, officers or agents in respect of which
indemnity may be sought pursuant to this Section 9, the Indemnified Party will promptly notify the
other Party (the “Indemnifying Party”) in writing (provided that the failure to give such notice
promptly will not prejudice the rights of an Indemnified Party, except to the extent that the
failure to give such prompt notice materially adversely affects the ability of the Indemnifying
Party to defend the claim, action or suit). Promptly after the Indemnified Party gives such
written notice, the Indemnifying Party and the Indemnified Party shall meet to discuss how to
respond to such claim, action or suit. The Indemnifying Party shall control the defense of such
claim, action or suit. The Indemnified Party shall cooperate with the Indemnifying Party in the
defense of such claim, action or suit, at the expense of the Indemnifying Party. In any such
proceeding, the Indemnified Party shall also have the right to retain its own counsel at its own
expense. The Indemnifying Party shall not be liable for Damages with respect to a claim, action or
suit settled or compromised by the Indemnified Party without the Indemnifying Party’s prior written
consent. No offer of settlement, settlement or compromise by the Indemnifying Party shall be
binding on an Indemnified Party without the Indemnified Party’s prior written consent (which
consent shall not be unreasonably withheld, conditioned or delayed), unless such settlement fully
releases the Indemnified Party without any liability, loss, cost or obligation to

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO
A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

24

 

such Indemnified Party, provided, however, that the Indemnifying Party shall have no authority
to take any action as part of any such defense or settlement that invalidates or otherwise
compromises or renders unenforceable the Indemnified Party’s Intellectual Property without the
Indemnified Party’s express prior written consent.

     9.5 Insurance. Each Party will procure and maintain, at its own expense, for the duration of
the Agreement, and for [†] thereafter if written on a claims made or occurrence reported form, the
types of insurance specified below with carriers rated A- VII or better with A. M. Best or like
rating agencies:

     (a) Workers’ Compensation accordance with applicable statutory requirements and each party
shall provide a waiver of subrogation in favor of the other party;

     (b) Employer’s Liability with a limit of liability in an amount of not less than [†]; and

     (c) Commercial General Liability including premises operations, products & completed
operations, blanket contractual liability, personal injury and advertising injury including fire
legal liability for bodily injury and property damage in an amount not less than [†] per occurrence
and [†] in the aggregate;

     Each Party shall include the other party and their subsidiaries, affiliates, directors,
officers, employees and agents as additional insured’s with respect to Commercial General Liability
and Excess Liability but only as their interest may appear by written contract. Each Party shall
make available to the other Party, at such other Party’s request, evidence of its maintenance of
insurance in satisfaction of its obligations under this Subsection 9.5. In the case of
cancellation, non-renewal or material change in said coverage, Each Party shall promptly provide to
the other Party with a new certificate of insurance evidencing that the coverage meets the
requirements in this Subsection 9.5. Each Party agrees that its insurance shall act as primary and
noncontributory from any other valid and collectible insurance maintained by the other Party. Each
party may, at its option, satisfy, in whole or in part, its obligation under this Subsection 9.5
through its self- insurance program, subject to the other party’s review and approval of the
sufficiency of such program.

     10. TERM; TERMINATION

     10.1 Term. This Agreement shall be effective as of the Effective Date, and shall continue for
[†] after the date of the first commercial sale of Product (the “Initial Term”), unless earlier
terminated in accordance with this Agreement. This Agreement shall automatically renew for up to
[†] additional [†] periods, commencing at the expiration of the Initial Term and any extensions
thereof, unless either Omeros or Hospira should terminate the Agreement by giving the other Party
written notice of intent to terminate at least [†] prior to the expiration of the Initial Term or
any extension thereof. The Initial Term as it may be extended shall be referred to herein as the
“Term.”

     10.2 Termination for Cause. Either Party shall have the right to terminate this Agreement (a)
for an uncured material breach by the other Party; or (b) for bankruptcy or insolvency of the other
Party, as further specified herein below in this Subection 10.2. In the

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO
A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

25

 

event that a Party materially breaches this Agreement, the other Party shall deliver written
notice to the breaching Party describing such breach in detail, which notice shall include a
statement of the non-breaching Party’s intent to terminate this Agreement unless such breach is
remedied. If the breaching Party does not cure such breach within sixty (60) days following
receipt of such written notice from the non-breaching Party, the non-breaching Party may terminate
this Agreement by sending a written notice of termination to the breaching Party In the event
that a Party goes into liquidation, or seeks the benefit of any bankruptcy or insolvency act, or a
receiver or trustee is appointed for its property or estate, or it makes an assignment for the
benefit of creditors, whether any of the aforesaid events be the outcome of the voluntary act of
such Party or otherwise, and such procedures are not terminated within ninety (90) days, the other
Party may terminate this Agreement by sending a written notice of termination to such Party.

     10.3 Termination by Omeros. Omeros shall have the right to terminate this Agreement at any
time, without penalty:

     10.3.1 for all countries, if, prior to Launch of the Product in any country in the Territory,
[†].

     10.3.2 on a country by country basis within the Territory, if, at any time before or after
Launch of the Product in such country(ies) in the Territory: [†].

     10.3.3 for all countries, if, after Launch of the Product in any country in the Territory:
[†].

     Except as specified above, termination of this Agreement as to any country in the Territory
shall not automatically terminate this Agreement for any remaining countries in the Territory.

     10.4 [†]

     10.5 Termination by Mutual Consent. The Parties may terminate this Agreement at any time by
mutual written consent.

     10.6 Effects of Termination.

     10.6.1 Return of Omeros Property and Product. Upon expiration or earlier termination of this
Agreement for any reason, Hospira shall return to Omeros all Omeros Property and Product (other
than samples retained under Subsection 3.6) within thirty (30) days after the date of such
expiration or termination.

     10.6.2 [†]

     10.6.3 Inventory. Upon termination pursuant to this Section 10, and except in instances of
breach by Hospira including without limitation failure of Product to meet Specifications, Omeros
shall purchase all inventory on hand and, if applicable, work in progress and reimburse Hospira for
Hospira’s cost of all supplies purchased and on hand or on order, if such supplies were ordered by
Hospira based on firm purchase orders or Omeros’ estimates of its requirements

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO
A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

26

 

of Product, and such supplies cannot be reasonably used by Hospira for other purposes.
Hospira shall invoice Company for all amounts due hereunder.

     11. FORCE MAJEURE

     11.1 Excuse from Performance. Either Party shall be excused from performing its respective
obligations under this Agreement if its performance is delayed or prevented by any event beyond
such Party’s reasonable control, including, but not limited to, acts of God, fire, explosion,
weather, disease, war, insurrection, civil strife, riots, government action, earthquake, terrorism,
or power failure; provided that such performance shall be excused only to the extent of and during
such disability and the affected Party shall use commercially reasonable efforts to resume
performance as soon as reasonably practicable. Any time specified for completion of performance
during or subsequent to the occurrence of any or all such events shall be automatically extended
for a commercially reasonable period of time to enable the affected Party to recover from such
disability. Hospira shall immediately notify Omeros if, by reason of any of the events referred to
herein, Hospira is unable to meet any such time for performance. Capacity constraints due to the
volume of business at Hospira shall not be deemed a force majeure event. If Hospira experiences a
force majeure event that interferes with Processing of Product at Hospira’s Facility, Hospira
shall, at Omeros’ discretion and request, cooperate in good faith with Omeros in expeditiously
transferring Processing to another of Hospira’s facilities, if available. The Parties shall
mutually discuss and implement in good faith an agreed-upon action plan for such transfer. The
Parties understand and agree that Omeros has chosen the excipient and primary container packaging
component suppliers listed in the Specifications and Hospira has agreed to such suppliers. In the
event that Hospira has reasonably objected in writing to the use of such suppliers based on
demonstrable quality or reliability concerns, and Omeros has unreasonably refused alternate
suppliers proposed by Hospira for reasons other than demonstrable quality or reliability concerns,
then under such circumstances, Hospira shall not have any liability to Omeros, nor shall Hospira be
deemed to be in breach of this Agreement, if Hospira is unable to supply Product to Omeros due to a
failure of such suppliers to provide such excipients and/or primary container packaging components
to Hospira.

     12. MISCELLANEOUS

     12.1 Governing Law. This Agreement shall be governed by and construed in accordance with the
laws of the State of Delaware, without regard to conflicts of laws or rules thereof.

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO
A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

27

 

     12.2 Dispute Resolution. In the event of a dispute arising from the performance of this
Agreement, each Party agrees to notify the other Party of the specific complaints or points of
disagreement, and to use its good faith efforts to resolve any such disputes without legal action.
Except for a dispute arising under Subsection 3.3 (which shall be resolved in accordance with
Subsection 3.3.4), in the event such good faith efforts fail, such dispute shall be first referred
to authorized executives of each Party (collectively, “Executives”) for resolution, upon one Party
providing the other Party with written notice that such dispute exists and has not been resolved.
The Executives shall attempt to resolve such dispute through good faith discussions prior to
instituting any civil action to resolve such dispute.

     12.3 Independent Contractors. For purposes of this Agreement, Hospira shall be deemed to be
an independent contractor and not an agent or employee of Omeros or a joint venturer with Omeros,
and nothing in this Agreement shall be construed to create any other relationship between Hospira
and Omeros. Neither Party shall have any right, power, or authority to assume, create, or incur
any expense, liability or obligation, expressed or implied, on behalf of the other Party. Hospira
shall be solely responsible for withholding and payment of all appropriate state and federal taxes,
including social security payments, with respect to all of its employees.

     12.4 Importer of Record. In the event any APIs or other Materials supplied by Omeros are
imported into the United States for delivery to Hospira, Omeros shall be the importer of record of
such APIs or other Materials, unless otherwise agreed with Hospira.

     12.5 Severability/Enforceability. If any provision(s) of this Agreement shall be held
invalid, illegal, or unenforceable by a court of competent jurisdiction, this Agreement shall
continue in full force and effect without said provision(s), consistent with the intent of the
Parties at the time of its execution. If deletion of such provision materially alters the basis of
this Agreement, then the Parties shall negotiate a good faith alternative.

     12.6 Modification/Waiver. This Agreement may not be altered, amended, or modified (nor shall
any obligation or breach be deemed waived) in any way, unless such alteration, amendment or
modification is in writing and signed by the Parties (or unless such waiver is in writing and
signed by the waiving Party). The failure of a Party to enforce any provision(s) of this Agreement
shall not be construed to be a waiver of the right of such Party to thereafter enforce that
provision or any other provision or right.

     12.7 Notices. All notices and demands required or permitted to be given or made pursuant to
this Agreement shall be in writing and shall be deemed given if delivered personally or by
facsimile transmission (receipt verified), mailed by registered or certified mail (return receipt
requested), postage prepaid, or sent by express courier service, properly addressed to the address
of the Party to be notified as shown below:

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO
A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

28

 

If to Hospira:

Hospira Worldwide Inc.

D-988, Building H1

275 North Field Drive

Lake Forest, Illinois 60045

Attention: VP & GM, One2One Global Contract Manufacturing Services

Facsimile: 224-212-3210

With a copy to:

Hospira, Inc.

Building H1, Dept NLEG

275 North Field Drive

Lake Forest, Illinois 60045

Attention: General Counsel

Facsimile: 224-212-2088

If to Omeros:

Omeros Corporation

1420 Fifth Avenue, Suite 2600

Seattle, Washington 98101

Attention: Chief Executive Officer

With a copy to: Vice President, Patent & General Counsel

Facsimile: 206-264-7856

or to such other address as to which either Party may notify the other. Any notice sent by
facsimile transmission shall be followed within twenty-four (24) hours by a signed notice sent by
first class mail, postage prepaid or by express courier service.

     12.8 Assignability. Neither Party may assign its rights and/or delegate its obligations under
this Agreement without the other Party’s prior written consent (which shall not be unreasonably
withheld or delayed); provided that either Party may assign or transfer this Agreement to any
successor in interest (whether by merger, acquisition, asset purchase or otherwise) to all or
substantially all of its business to which this Agreement relates, provided that the assigning
Party shall provide written notice to the other within thirty (30) days prior to such assignment.
The obligations and rights under this Agreement shall be binding upon all permitted assigns.

     12.9 Public Announcements. Subject to disclosures permitted under Subsections 8.1, 8.2 and
8.3 or as otherwise required by law or regulation, no public announcement relating to this
Agreement shall be made by either Party without the prior written consent of the other Party, and
neither Party shall use the other Party’s name, trademark or trade name, or the name of any
employee of the other Party, in any advertising or news release (including, without limitation, any
posting on the worldwide web) without the prior written consent of the other Party.

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO
A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

29

 

     12.10 Binding Effect. This Agreement shall be binding upon and inure to the benefit of the
Parties hereto and their respective successors and permitted assigns.

     12.11 Survival. The following Sections and Subsections shall survive the termination or
expiration of this Agreement for any reason: Sections 1 (to the extent definitions are embodied in
the following Sections and Subsections), 4, 5, 7, 8, 9, 11 and 12 and Subsections 2.2.1, 3.1 (for
Processed Product), 3.2, 3.3, 3.4 (except for replacement of non-conforming Product), 3.6 and 3.7
(with respect to retention of samples), 3.12, 3.13, 5.1-5.4, 5.6, 5.7, 5.8 and 10.6.

     12.12 Integration. This Agreement including any Exhibits hereto, shall constitute the entire
Agreement between the Parties with respect to the subject matter hereof, and shall supersede all
prior communications, understandings, and agreements (including any prior confidentiality
agreement) with respect thereto.

     12.13 Counterparts. This Agreement may be executed by original or facsimile signature in two
or more counterparts, each of which shall be deemed an original and all of which together shall
constitute one and the same instrument.

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO
A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

30

 

     IN WITNESS THEREOF, the Parties have caused this Agreement to be duly executed as of the
Effective Date.

	 	 	 	 	 
	 	OMEROS CORPORATION

 	 
	 	By:  	/s/ Gregory A. Demopulos
 	 
	 	Gregory A. Demopulos, M.D. 	 
	 	Chairman & CEO 	 
	 
	 	HOSPIRA WORLDWIDE, INC.

 	 
	 	By:  	/s/ Thomas Moore
 	 
	 	Thomas Moore 	 
	 	President, Global Pharmaceuticals 	 
	 

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO
A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

31

 

EXHIBIT A

PRODUCT ATTRIBUTES

Commercial Product

	  §	 	Manufactured at Hospira’s McPherson, Kansas facility [†]
	 
	  §	 	[†]
	 
	  §	 	[†]
	 
	  §	 	[†]
	 
	  §	 	[†]
	 
	  §	 	Bulk APIs to be supplied by Omeros, [†].
	 
	  §	 	[†]
	 
	  §	 	Release testing to be performed by Hospira with issuance of a Certificate of Analysis
	 
	  §	 	[†]

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO
A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

 

EXHIBIT B

PRODUCT PRICING

[†]

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO
A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

 

EXHIBIT C

PRODUCT STABILITY MATRIX

A stability time point matrix shall be mutually agreed in writing.

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO
A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSIONexv10w29

 

Exhibit 10.29

EXCLUSIVE LICENSE AND SPONSORED RESEARCH AGREEMENT

between

OMEROS CORPORATION and the UNIVERSITY OF LEICESTER

     This license agreement (the “Agreement”) is made effective the 10th day of June 2004 (the
“Effective Date”) between Omeros Corporation, a Washington corporation having a principal place of
business at 1420 Fifth Avenue, Suite 2600, Seattle WA 98101 USA (“Omeros”) and the University of
Leicester, having a principal place of business at University Road, Leicester LE1 7RH, United
Kingdom (“Leicester”).

     WHEREAS Leicester owns rights to certain technology related to mannan-binding lectin
associated serine protease-2 (“MASP-2”) and a MASP-2 related plasma protein of 19 kDa commonly
referred to as “MAp19”, which technology was developed in whole or in part by Wilhelm J. Schwaeble,
Ph.D., (“Dr. Schwaeble” or the “Principal Investigator”) and Cordula M. Stover, Ph.D. (“Dr.
Stover”), both employees of Leicester, and has obtained ownership of related technology developed
by Teizo Fujita (“Dr. Fujita”) of the Fukushima Medical University, School of Medicine
(“Fukushima”); and

     WHEREAS Omeros wishes to undertake an exclusive license in Leicester’s MASP-2 and MAp19
technology (including the related technology developed by Dr. Fujita), and to sponsor further
research to develop Leicester’s MASP-2 and MAp19 technology at Leicester under the direction of the
Principal Investigator; and

     WHEREAS Leicester wishes to grant Omeros an exclusive license in Leicester’s
MASP-2 and MAp19 technology (including the related technology developed by Dr. Fujita) in
return for potential royalty payments and sublicense revenue sharing, and to accept payment for
such sponsored research;

     NOW THEREFORE, in consideration for the mutual covenants and obligations set forth herein as
well as other good and valuable consideration, the parties hereby agree as follows:

	1	 	Definitions
	 
	1.1	 	Reference to “Leicester” and “Omeros” in regards to any intellectual property right developed
by the respective party shall be construed to refer to the respective party as well as the
respective party’s employees, officers, directors, consultants and agents.
	 
	1.2	 	“Intellectual Property Rights” shall mean all inventions, ideas, discoveries, issued,
reissued or reexamined patents, pending and future patent applications, continuation,
continuation-in-part and divisional patent applications, utility models, inventor’s
certificates, trade secrets, know-how, copyrights and trademarks.
	 
	1.3	 	“Sponsored Research” shall mean all research activities carried out by Leicester and/or its
employees (as may be agreed by Leicester and Omeros) with the financial sponsorship, in whole
or in part, by Omeros in accordance with Section 2 herein below or as otherwise agreed.

 

	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-1-

 

	1.4	 	“Leicester IP” shall mean all Intellectual Property Rights owned or held by Leicester,
including without limitation all such Intellectual Property Rights arising from the work of
Dr. Schwaeble, Dr. Stover, and/or other Leicester employees as well as that acquired under an
assignment agreement from Dr. Fujita, prior to the Effective Date of this Agreement, or
developed or obtained by Leicester after the Effective Date of this Agreement both (a)
independently of Omeros (as determined by inventorship under US law with respect to any
patents and patent applications) and (b) independently of the Sponsored Research, provided
however that in the event and to the extent that such independently developed Intellectual
Property Rights arise as the direct result of sponsorship by a not-for-profit enterprise in
accordance with Section 4.3 herein, such independently developed Intellectual Property Rights
shall be included within the scope of the license granted herein only if Leicester or
Leicester employee(s) obtain an assignment or release of such independently developed
Intellectual Property Rights from such not-for-profit enterprise, which assignment or release
Leicester shall exert all reasonable efforts to obtain or to cause its employees to obtain,
provided always that any of the Intellectual Property Rights described above in this section
1.4 are directly related to compositions, antibodies and/or methods for the inhibition of
MASP-2 and/or MAp19 and/or the diagnosis and/or treatment of MASP-2 or MAp19 mediated
disorders and/or deficiency syndromes, as well as methods, polynucleotides, polypeptides,
sequences and tools related to the development and production of MASP-2 or MAp19 antibodies
including without limitation murine, human, humanized and recombinant antibodies, murine lines
in which MASP-2 or MAp19 genes have been knocked-out or knocked-in, and all Intellectual
Property Rights in the subject matter disclosed or claimed in the draft patent application
entitled Genetically modified non-human mammals and cells filed in the British Patent
Office on 10 June 2004 and attached hereto as Exhibit A [†].
	 
	1.5	 	“Omeros IP” shall mean all Intellectual Property Rights owned or held by Omeros prior to the
Effective Date of this Agreement, or developed or obtained by Omeros after the Effective Date
of this Agreement independently of Leicester (as determined by inventorship under US law with
respect to any patents and patent applications), including without limitation all such
Intellectual Property Rights related to methods and pharmaceuticals or other agents to inhibit
pain, inflammation, cartilage loss, vasospasm, smooth muscle spasm, restenosis, or tumor cell
adhesion, and/or to accelerate recovery of joint motion and function, for use in surgical
procedures (including without limitation arthroscopic, cardiovascular, urologic and general
surgical procedures), other medical procedures, and/or for treatment of cartilaginous
disorders, and drug delivery methods and systems.
	 
	1.6	 	“Joint IP” shall mean (a) all Intellectual Property Rights in technology that is developed
jointly (as determined by inventorship with respect to any patents and patent applications) by
Omeros and Leicester (as may be agreed by Leicester and Omeros) during the Sponsored Research
Term (as that term is defined in Section 2.2 herein), and (b) all Intellectual Property Rights
arising from and as the direct result of the Sponsored Research. Should Dr. Schwaeble or
other Leicester employees enter into a consulting agreement with Omeros for general scientific
consulting such as in the field of

 

	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-2-

 

	 	 	inflammation, then to the extent that such scientific consulting services may pertain to
MASP-2 and MAp19, the results of such scientific consulting services will be treated as part
of the Joint IP. However, the parties acknowledge herein that research by Dr. Schwaeble and
other Leicester employees on behalf of Omeros related to MASP-2 and MAp19 will be carried
out in major part through the Sponsored Research.
	 
	1.7	 	[†]
	 
	1.8	 	“Licensed Products” shall mean all antibodies, inhibitors and all other products that, were
it not for the license granted to Omeros under this Agreement, infringe, or the use,
manufacture, offer for sale or sale of which infringe any valid and subsisting claim(s) of any
issued patent or any patentable claim(s) of any pending patent application included within the
Leicester IP in the country or countries in which such products are offered for sale, sold,
manufactured or used, excluding all products that would be included within the Licensed
Products in accordance with the above definition only because they are products that infringe
any claim(s) within the [†].
	 
	1.9	 	“Licensed Research Products” shall mean any antibodies that are not Licensed Products and
which are produced or developed as the direct result of use of murine line(s) that, were it
not for the license granted to Omeros under this Agreement, infringe, or the use of which
infringe, any valid and subsisting claim(s) of any issued patent or any patentable claim(s) of
any pending patent application for such murine line(s) included within the Leicester IP in the
country or countries in which such lines are propagated or used.
	 
	1.10	 	“Net License Proceeds” shall mean the total of the gross monetary amounts invoiced and
collected by Omeros for Licensed Products and Licensed Research Products (or that portion of
the value of any combination product attributed to a Licensed Product or a Licensed Research
Product included therein) used, manufactured, directly sold or directly distributed by Omeros,
less (a) the sum of the following actual and customary deductions where applicable: cash,
trade, or quantity discounts; sales, use, tariff, import/export duties or other excise taxes,
and any other governmental taxes imposed on particular sales; transportation charges and
allowances; commissions to third party sales agents; and credits to customers because of
rejections or returns and (b) any accrued Omeros IP Legal Fees (as defined below) not
previously deducted. For purposes of this paragraph, the acquisition of Licensed Products and
Licensed Research Products from Omeros as part of an acquisition of all or a substantial part
of the assets of Omeros’ business to which this Agreement pertains shall not be considered a
manufacture, sale or distribution.
	 
	1.11	 	“Net Sublicense Proceeds” shall mean the total of all sublicense royalties or sublicense fees
received by Omeros from third parties to which Omeros grants a sublicense under the Leicester
IP for the manufacture, sale or distribution of Licensed Products or Licensed Research
Products, and which were not included in the Net License Proceeds, less any accrued Omeros IP
Legal Fees not previously deducted, provided however that the Net Sublicense Proceeds shall
not include any fees or payments from such third parties to Omeros to support research and
development efforts, to purchase equity in Omeros, or for
any other purpose other than as compensation for sublicense rights.

 

	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-3-

 

	1.12	 	“Omeros IP Legal Fees” shall mean the sum of all legal fees and costs incurred by Omeros to
(a) evaluate, apply for, prosecute and maintain any Intellectual Property Rights included
within the Leicester IP, including without limitation any such fees and costs paid by Omeros
as reimbursement to Leicester for such fees and costs incurred by Leicester, and (b) obtain or
assist Leicester in obtaining or attempting to obtain clear, defensible, lawful and
uncontested title to the Leicester IP, including without limitation all such fees and costs
incurred in [†].
	 
	1.13	 	“Third Party License Fees” shall mean all royalties or other fees paid by Omeros to third
parties for a license from such third parties under Intellectual Property Rights owned or held
by such third parties for the manufacture, use, offer for sale, sale or distribution of
Licensed Products or Licensed Research Products, but shall exclude that portion of any such
third party royalties or other fees paid by Omeros attributed to items sold in combination
with the Licensed Products or the Licensed Research products, which items are not Licensed
Products or Licensed Research products.
	 
	2	 	Sponsored Research
	 
	2.1	 	Leicester shall perform research to be conducted by or under the direction of the Principal
Investigator (as may be agreed between Leicester and Omeros), directed to advancing the
technology included in the Leicester IP or related technology concerning the characterization
and inhibition of MASP-2 or MAp19, supported by the financial sponsorship of Omeros, and
without the use of third party sponsorship that would provide any intellectual property rights
in the results of the Sponsored Research to such third party, in accordance with one or more
research plans (“Research Plans”) agreed to in advance in writing between Leicester and
Omeros. An initial Research Plan is attached hereto as Exhibit B. No Research Plan or any
amendment thereto shall be effective until executed by Leicester and Omeros, and upon mutual
execution shall be automatically incorporated into this Agreement. Each Research Plan shall
define scientific aims, objectives and activities, a budget and a timeline for performance of
Sponsored Research during the corresponding time period.
	 
	2.2	 	The Sponsored Research shall be completed over a term (the “Sponsored Research Term”) that
will initially run for a period of one (1) year from the appointment or designation of
appropriate and mutually acceptable staff at Leicester, and that is extendable annually upon
mutual written agreement for a total term of three (3) years from the Effective Date of this
Agreement or as may otherwise be mutually agreed in writing. If Omeros or Leicester does not
wish to extend the Sponsored Research Term for the second or the third year, such party shall
provide the other party notice of non-extension at least ninety (90) days prior to the end of
the preceding year. The Sponsored Research Term shall run independently of the License Term
(as defined herein below) of this Agreement. Termination of this Agreement shall result in
termination of the Sponsored Research Term, but termination of the Sponsored Research Term,
such as in
accordance with Section 14.4 herein, shall not affect the overall status of this Agreement
or the License Term.

 

	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-4-

 

	2.3	 	Leicester shall supply all necessary personnel, administrative management, facilities,
equipment and supplies to enable timely completion of the Sponsored Research. Reimbursement
for Leicester’s costs and expenses for the Sponsored Research shall be provided only to the
extent agreed to in writing in the applicable Research Plan. Each Research Plan will be
completed diligently by Leicester using best efforts in accordance with prevailing
professional standards and all applicable laws, regulations and Leicester’s official policies.
Should the Principal Investigator become unavailable to complete any Research Plan, Leicester
and Omeros may agree on a substitute investigator, and in the event that a mutually acceptable
substitute is not available, either party may terminate the Sponsored Research Term.
	 
	2.4	 	Within thirty (30) days of the end of each quarter of the Sponsored Research Term, Leicester
shall submit a status report in written and electronic form (“Status Report”) summarizing the
results of the research completed during that quarter, except that annually within thirty (30)
days of the end of each year of the Sponsored Research Term or at such other point in time as
may be mutually agreed in writing, Leicester shall submit a final status report in written and
electronic form (“Final Report”) detailing the results of the research completed during such
year of the Sponsored Research Term. Upon Omeros’ request, Leicester shall complete all
requested corrections and make reasonable revisions to each Status Report and/or Final Report
to place it into a form suitable to meet Omeros’ objectives, including potential use of any
Status Report and/or any Final Report as part of any regulatory submissions.
	 
	2.5	 	In full and complete consideration for the Sponsored Research completed by Leicester during
the Sponsored Research Term in accordance with the Research Plan(s), Omeros shall pay
Leicester [†] for the first year, and unless a change in the level of Sponsored
Research work is agreed to in writing in subsequent Research Plans, this amount shall be
increased by [†] per year plus, in the event of continued use of a Leicester
laboratory technician in performing Sponsored Research activities after the first year of the
Sponsored Research Term, any increase in fees due to British national standard pay scale
changes applicable on a pro rata basis to such Leicester laboratory technician’s Sponsored
Research activities, for each mutually agreed subsequent year of the Sponsored Research Term
throughout which Sponsored Research is carried out (i.e., a total of [†] if the
Sponsored Research Term is extended for a total three-year period and the level of Sponsored
Research work during each year remains constant), payable at the rate of [†] of the
annual amount per quarter within thirty (30) days of the end of each quarter within the
Sponsored Research Term, provided however that no payment shall be due for any quarter prior
to the receipt and acceptance by Omeros of a Status Report or any Final Report, as
appropriate, for the respective quarter or year.
	 
	2.6	 	Omeros and the Principal Investigator shall collaborate on any proposed scientific
publications of Sponsored Research data and results, including a discussion of authorship
and contents. Leicester shall furnish Omeros with copies
of any publication or written or oral disclosure that is
proposed by Leicester, including, without limitation,
disclosures in papers or abstracts or at research seminars,
lectures, professional meetings, or poster sessions, at
least sixty (60) days prior to the proposed date for
submission for publication

 

	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-5-

 

	 	 	or disclosure. During such
60-day period, Omeros shall have the right to review and
comment on such publication for accuracy and protection of
confidential information. Additionally, upon Omeros’
written request during the foregoing 60-day period, the
proposed submission for publication or disclosure shall be
delayed until Omeros has completed the filing of patent
applications directed to information contained in such
proposed publication or disclosure or based on Omeros’
reasonable determination that publication should be delayed
due to other business considerations, but in no event will
such delay exceed an additional ninety (90) days following
the initial 60-day period without Leicester’s written
consent, which consent shall not be unreasonably withheld.
Omeros shall have the right, in its sole discretion, to
use, disclose, disseminate and publish (with due
acknowledgement of authorship) all data and results arising
out of the Sponsored Research for any and all purposes,
including without limitation in and for submissions to any
regulatory agencies and in marketing any products
including, but not limited to, Licensed Products and
Licensed Research Products.
	 
	3	 	Ownership of Intellectual Property
	 
	3.1	 	All Leicester IP shall remain owned or held by Leicester to the same extent as would be the
case were it not for this Agreement.
	 
	3.2	 	All Omeros IP shall remain owned or held by Omeros to the same extent as would be the case
were it not for this Agreement.
	 
	3.3	 	All Joint IP shall be jointly owned by Omeros and Leicester, i.e., Omeros and Leicester each
shall hold a 50% undivided joint ownership interest in all Joint IP.
	 
	4	 	Grant Of License
	 
	4.1	 	Leicester hereby grants to Omeros for the term of this Agreement a royalty-bearing,
world-wide exclusive license in the Leicester IP for the research, development, manufacture,
use, sale, offering for sale, distribution, exportation and importation of any and all
products and the practice of all methods within the Leicester IP, including without limitation
the exclusive right to develop, manufacture, use, sell, offer for sale, distribute, export and
import the Licensed Products and the Licensed Research Products and to use all murine lines
within the Leicester IP for all purposes including without limitation the research,
development and production of antibody products.
	 
	4.2	 	Leicester hereby grants to Omeros a fully-paid up, irrevocable, world-wide exclusive license
in and to Leicester’s joint ownership interest in the Joint IP, for the manufacture, use,
sale, offering for sale, distribution, exportation and importation of any and all products and
the practice of all methods encompassed by the Joint IP.
	 
	4.3	 	Subject to publication approval and timing procedures consistent with Section 2.6 herein,
Leicester shall retain the right to use the Leicester IP and the Joint IP for the purpose of
conducting non-commercial, academic research, including research sponsored by not-for-profit
entities, which shall not include the performance of research sponsored (directly or

 

	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-6-

 

	 	 	indirectly) by or on behalf of any for-profit entity that is in direct competition with Omeros
in a technology, product or research tool that is the subject of the Leicester IP or Joint IP.
	 
	4.4	 	Omeros shall have the right to grant sublicenses in the Leicester IP and the Joint IP under
this Agreement subject, with respect to the Leicester IP, to Omeros’ obligations to share
sublicense revenues as set forth in Section 5.
	 
	4.5	 	As part of the licenses granted to Omeros under Sections 4.1 and 4.2, Leicester agrees to
transfer and provide and/or make available to Omeros upon request progeny from the licensed
murine lines, cell lines, biological materials and any other research materials encompassed by
or included within the Leicester IP and/or the Joint IP to which Leicester has appropriate
rights and access, all such materials being provided on the basis of Omeros reimbursing
Leicester for Leicester’s actual cost in providing such materials but for no additional
consideration.
	 
	4.6	 	Leicester also grants to Omeros a right of first refusal for an exclusive license in all of
Leicester’s Intellectual Property Rights, for which Omeros has not already been granted a
license hereunder, and for which Leicester has all necessary rights to offer such first
refusal, and Leicester shall exert reasonable efforts to obtain such necessary rights, in (1)
any commercially applicable technology that arises during the Term of this Agreement and is
directly related to MASP-2 and/or MAp19 as more fully defined in the Leicester IP and the
Joint IP, and (2) any technology that has been developed through the contribution of both
Omeros and Leicester after the Sponsored Research Term.
	 
	5	 	Royalties and Sublicense Revenue
	 
	5.1	 	Omeros shall pay Leicester on a quarterly basis a royalty for Licensed Products of
[†] of the that portion of the Net License Proceeds realized during each respective
quarter from Licensed Products (the “Licensed Product Royalty”), provided however that Omeros
shall be entitled to deduct from the Licensed Product Royalty any accrued Third Party License
Fees paid by Omeros on the Licensed Products not already deducted, but in no event shall Third
Party License Fees be permitted to be deducted to an extent that such Third Party License Fees
would reduce the Licensed Product Royalty by greater than [†] for any given quarter.
	 
	5.2	 	Omeros shall pay Leicester on a quarterly basis a royalty for Licensed Research Products (the
“Licensed Research Products Royalty”) of (a) [†] of that portion of the Net License
Proceeds realized from Licensed Research Products during each respective quarter during and
only during the first [†] period following initial introduction of the relevant
product to a commercial market, and (b) [†] of that portion of the Net License
Proceeds realized from Licensed Research Products during each respective quarter after the
first [†] period
until such time that any third party should introduce into a commercial market a competing
product that does not infringe the Leicester IP, after which third-party introduction no
further Licensed Research Products Royalty shall be payable for the relevant product,
provided however that Omeros shall be entitled to deduct from the

 

	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-7-

 

	 	 	Licensed Research Products
Royalty any accrued Third-Party License Fees paid by Omeros on Licensed Research Products
not already deducted, but in no event shall Third-Party License Fees be permitted to be
deducted to an extent that such Third Party License Fees would reduce the Licensed Research
Products Royalty by greater than [†] for any given quarter.
	 
	5.3	 	Omeros shall pay Leicester on a quarterly basis a share of that portion of the Net Sublicense
Proceeds collected by Omeros on Licensed Products and collected by Omeros (“Sublicensed
Product Revenue Share”) from sublicensed third parties during each respective quarter, such
Sublicensed Product Revenue Share being either (a) [†] for any sublicenses in
connection with the Licensed Products granted hereunder prior to the earlier of (i)
[†], or (ii) the second year anniversary of the Effective Date of this Agreement, or
(b) [†] for any sublicenses in connection with the Licensed Products granted
hereunder thereafter.
	 
	5.4	 	Omeros shall pay Leicester on a quarterly basis a “Sublicensed Research Product Revenue
Share” that is (a) an initial percentage share (“First Share Percentage”) of that portion of
the Net Sublicense Proceeds realized from Licensed Research Products and collected by Omeros
from sublicensed third parties during each respective quarter during and only during the first
[†] period following initial introduction to a commercial market of the relevant
antibody product by the respective sublicensee, and (b) a subsequent percentage share (“Second
Share Percentage”) of that portion of the Net Sublicense Proceeds realized from Licensed
Research Products and collected by Omeros from sublicensed third parties during each
respective quarter after the initial [†] period. For any sublicenses in connection
with Licensed Research Products granted hereunder prior to the earlier of (i) [†], or
(ii) the second year anniversary of the Effective Date of this Agreement, the First Share
Percentage shall be [†] and the Second Share Percentage shall be [†]. For
any sublicenses in connection with Licensed Research Products granted hereunder thereafter,
the First Share Percentage shall be [†] and the Second Share Percentage shall be
[†].
	 
	5.5	 	Omeros shall promptly provide Leicester with a copy of all sublicenses granted by Omeros in
the Leicester IP and/or the Joint IP under this Agreement.
	 
	5.6	 	Following receipt from the University of the results of all Sponsored Research and the
completion of all other necessary and beneficial research activities by Omeros and/or by
others to support appropriate government regulatory submissions by Omeros, [†],
Omeros shall use reasonable efforts, based on reasonable commercial prudence, to diligently
develop and introduce to the market one or more Licensed Products and/or Licensed Research
Products. Ongoing performance of research and/or development efforts to generate or further
advance one or more Licensed Products and/or Licensed Research
Products by Omeros, internally at Omeros and/or under contract with Leicester and/or a third
party, shall be deemed to be diligent efforts under this Section 5.6.
	 
	5.7	 	It is Omeros’ current intent to commercially develop and seek regulatory clearance to
clinically test and then market an inhibitor of MASP-2 and/or MAp19 activity following

 

	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-8-

 

	 	 	Leicester’s identification of selective and high-affinity inhibitors of MASP-2 and MAp19
activity and demonstration by Leicester of the therapeutic benefit of such inhibitors in
animal models. Within three months of the identification by Omeros of a Licensed Product or
Licensed Research Product that is determined by Omeros to be a viable and optimal clinical
development candidate, Omeros will submit a development plan to Leicester that sets forth
Omeros’ planned activities and estimated timing for the development, regulatory approval and
market introduction of one or more Licensed Products and/or Licensed Research products.
Assuming anticipated and adequate progress is made in the Sponsored Research [†],
Omeros anticipates the identification of an initial potential candidate for a Licensed Product
or Licensed Research Product that is a potential clinical development candidate within two
years of the commencement of the Sponsored Research. The foregoing statements within this
Section 5.7 and such development plan are or will be provided as indications of current or
future intentions only, and shall have no binding effect on Omeros, nor shall it give rise to
any right or obligation to either party, and any modification, alteration or failure to meet
any of these intentions shall have no impact on this Agreement.
	 
	6	 	Payments
	 
	6.1	 	Quarterly royalty and sublicense revenue payments shall be made in British Pounds Sterling by
Omeros to Leicester within sixty (60) days of the end of the quarter. Payments shall be
computed based on a conversion from any other denomination to British Pounds Sterling for any
revenues received or costs and expenses incurred by Omeros during the relevant quarter or
other reporting period, as provided herein, using the prevailing exchange rate in effect at
the date and time that funds are transferred from Omeros’ account to Leicester’s account (in
the case of payment by wire transfer) or at the date and time of issuance of a check by Omeros
(in the case of payment by check). Each quarterly payment shall be accompanied by a report
specifying (a) the source of the royalties itemized by product and country, (b) any Omeros IP
Legal Fees or Third Party License Fees that were deducted from gross proceeds to determine Net
License Proceeds or Net Sublicense Proceeds as provided in Sections 1.10 or 1.11 of this
Agreement, and (c) the total of all discounts, returns, credits and commissions deducted from
gross proceeds to determine Net License Proceeds or Net Sublicense Proceeds as provided in
Sections 1.10 or 1.11 of this Agreement. Following the two-year anniversary of the Effective
Date of this Agreement, in the event that Omeros receives no such quarterly royalty and
sublicense revenue in any given quarter, it shall nevertheless submit a quarterly report to
that effect to Leicester within sixty (60) days of the end of the quarter.
	 
	6.2	 	Leicester reserves the right to employ a certified public accountant to review and reconcile
the directly relevant accounting records and procedures of Omeros as they relate
to the determination of royalties or sublicense revenue fees under Section 5 herein during
reasonable business hours and no more than twice a year, and Omeros agrees to make available
at Omeros’ place of business all such directly relevant accounting records for that purpose
within 30 (thirty) days of written request by Leicester. The cost of such review shall be
borne by Leicester, unless it is found that Omeros under-paid a quarterly royalty or
sublicense revenue fees for any quarter by an amount of 10% (ten percent) or

 

	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-9-

 

	 	 	greater, in
which case the cost of such review shall be borne by Omeros.
	 
	6.3	 	In the event any royalty or sublicense revenue fee payments due under Section 5 herein are
not timely paid by Omeros, Omeros shall pay to Leicester interest charges on such late
payments at a rate of [†] per annum.
	 
	6.4	 	Not withstanding anything to the contrary herein, Omeros shall have no obligation to pay any
royalties or sublicense revenue fees under Section 5 for any product based on any patent claim
that has been declared invalid or unenforceable by a court or governmental body of competent
jurisdiction or based on any patent claim that is not enforceable in the jurisdiction(s) where
such products are manufactured, used, sold, offered for sale, imported or distributed.
	 
	7	 	License Progress
	 
	7.1	 	Omeros shall on an annual basis, commencing on the one-year anniversary of the Effective Date
of this Agreement and annually thereafter, deliver to Leicester within thirty (30) days after
the end of the respective year a written progress report detailing the status of Omeros’
efforts to fund, patent, develop and commercialize Licensed Products and Licensed Research
Products.
	 
	8	 	Patent Prosecution
	 
	8.1	 	Omeros shall have the sole right at its discretion to apply for, prosecute and maintain
patents for inventions included within the Leicester IP and the Joint IP (“Patent Filings”) in
the name of the legally appropriate inventors and/or parties to this agreement and/or jointly
with third parties as may be legally appropriate, provided however that (a) Omeros shall bear
all cost and expense for all such Patent Filings, subject to the right to deduct Omeros IP
Legal Fees as set forth herein, (b) Omeros shall keep Leicester timely informed of the
progress of all Patent Filings and timely provide Leicester copies of all official
documentation related to such Patent Filings, (c) at Omeros’ discretion and until such time
that Omeros provides a written request for transfer of responsibility, Leicester shall
continue at Omeros’ cost with the prosecution of any patent applications for the Leicester IP
it may have filed prior to the Effective Date of this Agreement, subject to consultation with
and direction from Omeros prior to taking any substantive action, but in any event Omeros
shall assume responsibility for prosecuting the patent application attached as Exhibit A
hereto within two months following the later of the filing of such patent application by
Leicester or the Effective Date of this Agreement, and (d) Omeros shall exert commercially
reasonable efforts to diligently pursue all Patent Filings to issuance or final determination
of unpatentability, provided however that if Omeros
determines at its sole discretion to not make Patent Filings for any commercially
significant inventions within the Leicester IP or the Joint IP in any countries of
commercial significance, or abandons any Patent Filing prior to issuance or final
determination of unpatentability, Omeros shall give Leicester advance written notice of such
determination, Leicester shall have the right thereafter to elect upon written notice to
Omeros to pursue such Omeros abandoned Patent Filings at Leicester’s sole expense,

 

	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-10-

 

	 	 	and such
Omeros abandoned Patent Filings shall be excluded from the scope of the licenses granted
under this Agreement.
	 
	8.2	 	Omeros shall reimburse Leicester for Leicester’s reasonable documented legal fees and costs
paid by Leicester for any patent applications prepared and/or filed or prosecuted by Leicester
for inventions within the Leicester IP prior to the effective date of this Agreement or in
accordance with Section 8.1 above. Payment for such reimbursed expenses shall be made within
thirty (30) days of Omeros’ having received a receipt-documented invoice from Leicester,
provided however that Leicester represents that all such legal fees and costs incurred by
Leicester prior to the effective date of this Agreement shall not exceed [†].
	 
	8.3	 	Leicester shall promptly provide written disclosure to Omeros of any inventions,
improvements, or applications included within the Leicester IP or Joint IP conceived,
developed, made or arising before or during the term of this Agreement. Leicester will
provide all reasonable assistance, including review of documents and the execution of all
documents and causing Leicester’s employees to review and execute all documents, necessary to
make, prosecute, maintain and enforce the Patent Filings, all for no additional consideration
but with reimbursement by Omeros of Leicester’s reasonable expenses for such assistance.
	 
	8.4	 	Leicester shall promptly provide written disclosure to Omeros of any and all potentially
material prior art known prior to the Effective Date of this Agreement or that becomes known
during the License Term of this Agreement to any Leicester employee that is associated with
this Agreement, the Sponsored Research, the Leicester IP or the Joint IP.

 

	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-11-

 

	9	 	Representations, Warranties and Other Obligations of Omeros
	 
	9.1	 	Omeros represents and warrants that it has the requisite corporate power and authority and
the legal right to enter into this Agreement and to perform its obligations hereunder.
	 
	9.2	 	Omeros has and will maintain reasonably adequate insurance coverage for employment practices
and general liability for all its activities under this Agreement. Prior to Omeros’ marketing
of any Licensed Product, Licensed Research Products, or product encompassed by the Joint IP,
or making any such products available for use in any human patients, Omeros will obtain and
maintain reasonably adequate product liability insurance.
	 
	10	 	Representations, Warranties and Other Obligations of Leicester
	 
	10.1	 	Leicester has disclosed to Omeros the existence of the [†] and information as to the
development of the Leicester IP, and Leicester warrants that it has made reasonable efforts to
ascertain the details of such development and that it reasonably believes the same to be true.
[†].
	 
	10.2	 	[†]
	 
	10.3	 	[†]
	 
	10.4	 	Leicester represents and warrants, subject to the disclosure referred to in Section 10.1,
that it is the owner of all right, title and interest in any and all inventions included
within the Leicester IP and the Joint IP made or to be made wholly or jointly by Leicester
employees, including without limitation those made by Dr. Schwaeble and Dr. Stover, and shall
cause Dr. Schwaeble and Dr. Stover to each execute this Agreement to confirm their agreement
to be bound to the same extent as Leicester with respect to all relevant provisions of this
Agreement.
	 
	10.5	 	Leicester represents and warrants that it is the owner of all right, title and interest in
any and all inventions that were made wholly or jointly by Dr. Fujita that are included within
the Leicester IP, has obtained an assignment from Dr. Fujita together with a release of all
such rights from Fukushima, has provided to Omeros a true copy of such assignment and release,
is under no restriction or obligation with respect to Dr. Fujita or Fukishima that is
inconsistent in any way with Leicester’s obligations under this Agreement, and that Omeros
shall have no obligation to compensate Dr. Fujita or Fukushima as the result of Omeros’
exercise of its rights and fulfillment of its obligations under this Agreement.
	 
	10.6	 	Subject to [†] as discussed in Section 10.1 above, Leicester represents and warrants
to Omeros that as far as it is aware, after having used reasonable efforts to ascertain
relevant facts and having formed a reasonable belief as to their truth, it has the lawful
right to grant the licenses conveyed under this Agreement, and that the Leicester IP and the
Joint IP are unencumbered by any third party obligation, commitment, restriction or license.
[†].

 

	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-12-

 

	10.7	 	[†], Leicester warrants that it is not aware of any third party rights that
would be infringed as a result of Omeros’ fulfilling the terms of this Agreement.
	 
	10.8	 	Leicester has and will maintain reasonably adequate insurance coverage for employment
practices and general liability for all its activities under this Agreement.
	 
	10.9	 	THE WARRANTIES SET FORTH EXPRESSLY IN THIS AGREEMENT ARE THE SOLE
WARRANTIES MADE BY EITHER PARTY TO THE OTHER AND THERE ARE NO OTHER WARRANTIES,
REPRESENTATIONS OR GUARANTEES OF ANY KIND WHATSOEVER, EITHER EXPRESS OR IMPLIED, REGARDING THE
LICENSED PRODUCTS, THE LICENSED RESEARCH PRODUCTS, OR OTHER PRODUCTS, INCLUDING
WITHOUT LIMITATION ANY EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A
PARTICULAR PURPOSE.
	 
	11	 	Confidentiality
	 
	11.1	 	Leicester and Omeros hereby affirm and incorporate by reference the terms of the Mutual
Nondisclosure Agreement between the parties dated September 23, 2003 concerning the subject
matter of this Agreement, a copy of which is attached hereto as Exhibit C, except to the
extent that the terms of such nondisclosure agreement may conflict with the terms of this
Agreement, in which case the terms of this Agreement shall prevail. The parties further agree
that the mutual obligations of nondisclosure and non-use set forth in such Mutual
Nondisclosure Agreement shall subsist for a period of five (5) years after the termination of
this Agreement.
	 
	11.2	 	The terms of this Agreement shall be maintained in strict confidence by both Leicester and
Omeros, and may not be disclosed by either party without the consent of the other party,
except as may be required under a court order or decree or as required to comply with any
governmental law, rule or regulation, and Omeros may disclose the terms of this Agreement to
Omeros’ current and potential employees, directors, consultants, shareholders, investors and
corporate partners.
	 
	12	 	Indemnification
	 
	12.1	 	Each party (the “Indemnifying Party”) shall indemnify, hold harmless and defend the other
party and its employees, officers, directors, consultants and agents (the “Indemnified Party”)
against any and all claims, suits, losses, liabilities, damages, costs, fees, and expenses
(“Claims”) resulting from or arising directly out of the Indemnifying Party’s breach of any
representation, warranty or obligation under this Agreement, or the Indemnifying Party’s
exercise of the rights and obligations under this license or any sublicense, except that such
obligation to indemnify, hold harmless and defend shall not extend to any Claims to the extent
such Claims result from or arise directly from the negligence or misconduct of the Indemnified
Party. This indemnification does not include any indemnity in relation to product performance
or product liability, and furthermore does not include any incidental, consequential or
special damages.

 

	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-13-

 

	13	 	Enforcement of Patent Rights
	 
	13.1	 	If either party learns of the infringement of any patent or other intellectual property right
included in the Leicester IP or the Joint IP, that party shall promptly notify the other party
of such infringement and will provide the other party with all evidence of infringement in the
notifying party’s possession. Both parties shall use their best efforts in cooperation with
each other to terminate third party infringement without litigation.
	 
	13.2	 	Omeros shall have the sole right at its discretion to enforce the Leicester IP and the Joint
IP against third party infringers, including the initiation of any civil action in Omeros’
name, at Omeros’ sole cost, in which event any award, judgment, settlement or damages
collected shall belong solely to Omeros without duty to account to Leicester. In the event
that it is necessary for Omeros to join Leicester as a party to any such civil action,
Leicester shall join such action for no additional compensation but at Omeros’ sole expense,
and any award, judgment, settlement or damages collected shall belong solely to Omeros without
duty to account to Leicester.
	 
	13.3	 	If Omeros unreasonably declines to initiate enforcement of the Leicester IP and the Joint IP
against any third party infringer within ninety (90) days of a written demand from Leicester
to do so, then Leicester shall have the sole right at its discretion to enforce the Leicester
IP and the Joint IP against such third party infringer, including the initiation of any civil
action in Leicester’s name, at Leicester’s sole cost, in which event any award, judgment,
settlement or damages collected shall belong solely to Leicester without duty to account to
Omeros.
	 
	14	 	Term and Termination
	 
	14.1	 	Unless terminated earlier as set forth in Section 14.2 or 14.3 herein below, this Agreement
shall subsist so long as there is any pending patent application within the Leicester IP or
the Joint IP, any patent application in the process of being prepared for filing as agreed to
by Omeros and Leicester or any valid and subsisting claim included within any patent, utility
model or inventor’s certificate within the Leicester IP or the Joint IP (the “License Term”).
	 
	14.2	 	Omeros may terminate this Agreement by providing ninety (90)-days advance written notice of
termination under this Section 14.2 to Leicester, with or without cause, [†].
	 
	14.3	 	Either party may terminate this Agreement at any time in the event that the other party
(a) breaches any material obligation of this Agreement by first submitting written notice of
breach to the breaching party, which breach is not substantially cured within ninety (90)
days of the receipt of such notice, followed by written notice of termination then being
sent to the breaching party, or (b) declares or is adjudged by a court of competent
jurisdiction to be insolvent, bankrupt or in receivership, and such insolvency, bankruptcy
or receivership materially limits such party’s ability to perform its obligation under this
Agreement, excluding reorganizations entered into by such party with the consent of the
other party, which consent shall not be unreasonably withheld.

 

	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-14-

 

	14.4	 	Omeros may at any time terminate its sponsorship of the Sponsored Research by providing
ninety (90)-days advance written notice of termination under this Section 14.4 to Leicester,
with or without cause, at any time, in which event Sections 2.1 — 2.3 herein shall cease to be
effective, and Sections 2.4 and 2.5 shall cease to be effective after all reports are provided
and accepted and all payments are made for Sponsored Research performed in accordance with the
applicable Research Plan prior to such notice, but the remainder of this Agreement shall
continue in full force and effect for the License Term, including all rights and obligations
of both parties hereunder. In the event of Omeros’ termination of its sponsorship of the
Sponsored Research under this Section 14.4, Omeros shall pay to Leicester any and all
non-cancelable sums reasonably incurred or committed to by Leicester prior to receipt of the
notice of termination.
	 
	14.5	 	The provisions of Sections 2.6 (Publication), 3 (Ownership of Intellectual Property), 4.2 –
4.6 (License as applicable to Joint IP and right of first refusal), 8 (Patent Prosecution as
applicable to Joint IP), 9 and 10 (Representations and Warranties and Other Obligations), 11
(Confidentiality), 12 (Indemnification), 13 (Enforcement as applicable to Joint IP), 15 (Use
of Names) and 16 (Miscellaneous) above shall survive expiration or termination of this
Agreement for the period set forth therein or, if no period is set forth therein, then
indefinitely.
	 
	15	 	Use of Names
	 
	15.1	 	Nothing contained in this Agreement confers any right to either party to use in advertising,
publicity, or other promotional activities any name, trade name, trademark, or other
designation of the other party hereto, and neither party shall make such use without the prior
written consent of the other party, provided however Omeros may through written, oral or
electronic communication disclose the existence of this Agreement and the names of Leicester,
Dr. Schwaeble, Dr. Stover, Dr. Fujita and other of Leicester’s employees and consultants to
Omeros’ current and potential employees, directors, consultants, shareholders, investors and
corporate partners, and as required to comply with any governmental law, rule or regulation.
	 
	16	 	Miscellaneous
	 
	16.1	 	This Agreement including all appendices and exhibits attached thereto or incorporated by
reference therein constitutes the entire understanding of the parties hereto regarding the
subject matter of this Agreement, and no other representation, agreement, promise or
undertaking altering, modifying, taking from or adding to the terms of this Agreement shall
have any effect unless the same is reduced to writing and duly executed by the parties hereto.
In the event of any conflict between the main body of this Agreement and any attachments
thereto or documents incorporated by reference therein, the provisions of the main body of
this Agreement shall control.
	 
	16.2	 	Either party’s failure to enforce any provision of this Agreement will not be considered a
waiver of future enforcement of that or any other provision.

 

	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-15-

 

	16.3	 	The laws of the state of Delaware, United States, without regard to its conflict-of-laws
provisions, shall govern this Agreement, its interpretation and its enforcement, and any
disputes arising out of or related to this Agreement.
	 
	16.4	 	The parties agree that, except as provided herein below, any claim or controversy arising out
of or relating to this Agreement or breach thereof shall be settled by arbitration in the
state of Delaware, United States, in accordance with the commercial rules of the American
Arbitration Association by a panel of three arbitrators, one selected by each party and the
third selected by the other two arbitrators. In any such arbitration proceeding, judgment
upon the award rendered by the arbitrator shall be final and binding upon the parties and may
be entered by either party in any court or forum of competent jurisdiction as provided herein
below. Notwithstanding the foregoing, both parties agree that any claims or controversies
concerning the validity or enforceability of any intellectual property, or the actual or
threatened disclosure or misuse of confidential information, may alternately be resolved by a
civil action in any court of competent jurisdiction as provided herein below, and both parties
further agree that each shall retain the right to seek injunctive relief in any court of
competent jurisdiction as provided herein below to prevent a breach, threatened breach or
continuing breach of this Agreement which would cause irreparable injury (e.g., breaches of
confidentiality or the like).
	 
	16.5	 	Any civil action prosecuted or instituted by either party as permitted herein above with
respect to any matters arising out of or related to this Agreement shall be brought in either
the United States District Court located in the state of Delaware, United States (if federal
subject matter jurisdiction therein lies) or the Superior Court for the state of Delaware,
United States (if there is no subject matter jurisdiction in federal court), and each party
hereby consents to the jurisdiction and venue of such courts for such purposes.
	 
	16.6	 	In the event that it is necessary for either party of this Agreement to take legal action to
enforce any of the terms, conditions or rights contained herein, or to defend any such action,
then the prevailing party in such action shall be entitled to recover from the other party all
reasonable attorneys fees, costs and expenses related to such legal action.
	 
	16.7	 	In the event that any portion of this Agreement is held invalid or unenforceable by a court
of law, that provision will be construed and reformed to permit enforcement of the provision
to the maximum extent permissible consistent with the parties’ original intent, and if such
construction is not possible, such provision shall be struck from this Agreement, and the
remainder of the Agreement shall remain in full force and effect as if such provision had
never been part of this Agreement.
	 
	16.8	 	For the purposes of this Agreement, the parties hereto are independent contractors, and
nothing in this Agreement shall be construed to place them in the relationship of partners,
principal and agent, employer/employee or joint venturers. Except as provided expressly
herein, each party agrees that it shall have no authority to bind or obligate the other party,
nor shall any party hold itself out as having such authority.

 

	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-16-

 

	16.9	 	Neither party will be liable for failure or delay in performing any obligation under this
Agreement, or will be considered in breach of this Agreement, if such failure or delay is
due to a natural disaster or any cause reasonably beyond such party’s control, provided that
such party resumes performance as soon as possible following the end of the event that
caused such delay or failure of performance.
	 
	16.10	 	Neither party may assign this Agreement, or any obligation or right under this Agreement, in
whole or in part, without the other party’s prior written consent, which consent will not be
unreasonably withheld. This Section shall not be construed in any way to limit Omeros’ rights
to grant, at Omeros’ sole discretion, sublicenses hereunder. Leicester consents to Omeros’
assignment of this Agreement in whole or in part in connection with the merger, consolidation
or transfer of all or substantially all of that portion of Omeros’ assets to which this
Agreement relates. Subject to these restrictions, this Agreement will be binding upon and
will inure to the benefit of the parties’ permitted successors and assignees.
	 
	16.11	 	Any notice required or permitted to be given hereunder by either party shall be in writing
and shall be (a) delivered personally, (b) sent by registered mail, return receipt requested,
postage prepaid, (c) sent by an internationally recognized courier service guaranteeing
next-day delivery, charges prepaid, or (d) delivered by facsimile (with the original promptly
sent by any of the foregoing manners) to the addresses or facsimile numbers of the other party
set forth below, or at such other addresses as may from time to time be furnished by similar
notice by either party. The effective date of any notice hereunder shall be the date of
receipt by the receiving party.

	 	 	 
	If to Omeros:

	 	If to Leicester:
	 
	 	 
	Omeros Corporation

	 	University of Leicester
	1420 Fifth Avenue, Suite 2600

	 	University Road
	Seattle, WA 98101

	 	Leicester, LE1 7RH
	U.S.A.

	 	United Kingdom
	 
	 	 
	Attention: Gregory A. Demopulos, M.D.,

	 	Attention: Research and
	Chairman & CEO

	 	Business Development Office
	 
	 	 
	And copy to: Marcia S. Kelbon,
	 	 
	Patent & General Counsel
	 	 
	 
	 	 
	Fax: (206) 264.7856

	 	Fax: +44 (0) 116.252.2028
	Phone: (206) 623.4688

	 	Phone: +44 (0) 116.252.2347

	16.12	 	This Agreement may be executed in one or more counterparts, each of which will be considered
an original, and all of which will constitute the same instrument.

 

	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-17-

 

     IN WITNESS WHEREOF, Omeros and Leicester have each acknowledged and accepted this Agreement by
causing it to have been signed by their respective duly authorized officials.

	 	 	 	 	 	 	 	 	 
	OMEROS CORPORATION	 	UNIVERSITY OF LEICESTER	 	 
	 
	 	 	 	 	 	 	 	 
	By:

	 	/s/ Gregory A. Demopulos
 

	 	By:
	 	/s/ Clare O’Neill
 

	 	 
	 
	 	 	 	 	 	 	 	 
	Name:

	 	Gregory A. Demopulos, M.D.
	 	Name:
	 	Clare O’Neill	 	 
	 

	 	 	 	 	 	 

	 	 
	 
	 	 	 	 	 	 	 	 
	Title:

	 	Chairman & CEO
	 	Title:
	 	Business Development Manager	 	 
	 

	 	 	 	 	 	 

	 	 
	 
	 	 	 	 	 	 	 	 
	Date:

	 	7/6/04
	 	Date:
	 	
10th June 2004	 	 
	 

	 	 

	 	 	 	 

	 	 
	 
	 	 	 	 	 	 	 	 
	Fax:

	 	206.264.7856
	 	Fax:
	 	0044 116 252 2028	 	 
	 

	 	 	 	 	 	 

	 	 

     The above Exclusive License and Sponsored Research Agreement is acceptable to the
undersigned investigators, who agree to abide by the terms set forth therein.

	 	 	 	 	 	 	 	 	 
	WILHELM J. SCHWAEBLE, PH.D.	 	CORDULA M. STOVER, PH.D.	 	 
	 
	 	 	 	 	 	 	 	 
	Signed:

	 	/s/ Wilhelm J. Schwaeble
	 	Signed:
	 	/s/ Cordula M. Stover	 	 
	 

	 	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	Title:

	 	Professor of Immunology
	 	Title:
	 	Lecturer in Immunology	 	 
	 

	 	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	Date:

	 	10/06/04
	 	Date:
	 	10 June 04	 	 
	 

	 	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	Fax:

	 	0044-116-252-5030
	 	Fax:
	 	0044-116-252-5030	 	 
	 

	 	 
	 	 	 	 	 	 

 

	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-18-

 

EXHIBIT A

To the Exclusive License and Sponsored Research Agreement

Between Omeros Corporation and the University of Leicester

PATENT APPLICATION

 

	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-19-

 

EXHIBIT B

To the Exclusive License and Sponsored Research Agreement

Between Omeros Corporation and the University of Leicester

RESEARCH PLAN

1st-Year Research Program Outline – Omeros and University of Leicester

     The following are the research aims of the Sponsored Research program for the first year. All
activities to meet the aims are to be carried out by Leicester (“Dr. Schwaeble’s lab”) except for
those aims noted for performance by Omeros, other investigators or contractors. Aims indicated as
to be performed by Omeros or third parties are provided herein for reference purposes only and
shall not be interpreted as any obligation on the part of Omeros. Specific aims and corresponding
timeline may be modified as mutually agreed in writing by Dr. Wilhelm Schwaeble and Omeros.

     Aims as set forth will extend into a second year of the Sponsored Research Program.

     Specific Aims:

     [†]

 

	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-20-

 

EXHIBIT C

To the Exclusive License and Sponsored Research Agreement

Between Omeros Corporation and the University of Leicester

MUTUAL CONFIDENTIALITY AGREEMENT

 

	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-21-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00135-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00135-of-00352.parquet"}]]